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ABSTRACT 
 
 Parkinson’s disease (PD) is a chronic and progressive condition that affects the 
physical, emotional, and social functioning of individuals. Freed et al. (2001) conducted a 
double-blind sham-controlled trial to investigate the effectiveness of fetal tissue 
transplantation of those with PD. The authors investigated the effects of the surgery 
across the dimensions of physical and neurological functioning. A quality of life (QoL) 
study was conducted to determine if there were differences in QoL when comparing 
those who received the fetal tissue transplantation to those who received the sham 
surgery (McRae et al., 2004).  
While there is little research on the effectiveness of fetal tissue transplantation as 
a treatment for PD, there is even less literature on longitudinal effects of this treatment. 
This study examined the longitudinal trajectory of change in QoL since participants 
received fetal transplant surgery 10-12 years ago. Participants included 11 people who 
were in the parent (Freed et al., 2001) and original QoL (McRae, 2004) studies. 
Participants completed a questionnaire that measured the dimensions of QoL along with a 
personality inventory, the NEO-FFI. Data gathered from the questionnaires were 
compared to baseline, one-year, and two-year information on the same participants. 
Trajectory of change in QoL and personality was assessed with a repeated measures 
analysis of variance.  
iii 
For the present study, significant changes over time were found for the Physical 
functioning (p < .05) and Emotional functioning (p < .10) dimensions of QoL. A 
significant result was also found for the Social functioning (p < .05) dimension of QoL 
that was measured by the Social Provisions Scale. In addition, significant results were 
found for the Neuroticism (p < .10), Extraversion (p < .05), Openness to Experiences (p < 
.05), and Conscientiousness (p < .10) factors of the NEO-FFI. Participants reported a 
decrease in Physical, Emotional, and Social functioning between the two-year and current 
assessments. Participants reported an increase in Neuroticism, and a decrease in 
Extraversion, Openness to Experience, and Conscientiousness between the two-year and 
current assessments. Findings of the current study provided longitudinal information on 
the trajectories of fetal tissue transplantation on QoL and personality for participants with 
PD.  
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Chapter One
Introduction 
 
 
Description of Parkinson’s Disease
 
Parkinson’s disease (PD) is a neurological disorder that is caused by a dysfunction 
of the brain. The major symptoms include tremor, slowness in starting and carrying out 
movements, or bradykinesia, rigidity or muscle stiffness, and difficulties with balance 
and walking (Jahanshahi & Marsden, 2000). The disease was named after the British 
doctor, James Parkinson, who first described PD in 1817.  
PD affects approximately one in 1,000 people, with incidence increasing as 
people age. Symptoms develop after the degeneration of at least 80% of dopamine-
producing neurons in the substantia nigra (Leader & Leader, 2001). The degeneration of 
dopamine neurons in the substantia nigra creates substantial physiological disturbances in 
the basal ganglia, thalamus, and cerebral cortex (Betchen & Kaplitt, 2003). The cause of 
degeneration in idiopathic PD is not known; however, it is known that the disease is not 
caused by behaviors, diet, or stress. Except for familial PD, heredity is not believed to be 
a major cause. It is theorized that certain individuals may have a genetic susceptibility to 
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developing PD. There are many theories about the cause of PD that are currently under 
investigation.  
PD can be treated and controlled with the appropriate medication for symptoms; 
however, it does affect activities of daily living and quality of life for individuals who 
have it. Many people with PD develop dementia, or intellectual decline and loss of 
memory. Cognitive problems such as absent-mindedness, slower thinking, and difficulty 
with tasks that require strong mental effort are also common.  
 
Onset and Prevalence 
 
In about 80% of PD cases, the age of onset occurs between the ages of 40 and 70 
years old. There is a peak age of disease onset around 60 years of age. It is uncommon for 
there to be an age of disease onset before 35 years old and after 75 years old in 
individuals (Leader & Leader, 2001). In young-onset PD, the illness develops between 
the ages of 21 and 40. Juvenile parkinsonism starts before the age of 21 and is very rare 
(Jahanshahi & Marsden, 2000).  
Although PD progresses slowly, there may be a more intense progression during 
the first years of the disease. Since levodopa (L-dopa) became the prime treatment for PD 
in the 1970s, life expectancy for those with PD has been similar to the general 
population. Individuals with PD are likely to die for the same reasons as the general 
public, except those with PD are less likely to smoke and ultimately develop cancer 
(Jahanshahi & Marsden, 2000).  
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Gender and Ethnicity Differences 
 
 Although some studies have stated that men are slightly more likely than women 
to develop PD, men and women are equally likely to be at risk for the illness (Jahanshahi 
& Marsden, 2000). The disease affects those from all socioeconomic backgrounds, 
occupations, and ethnic groups, and is not geographically limited.  
 
Symptoms 
  
There are certain symptoms that are common initial features for those with PD. 
The first common initial symptom is tremor. The tremor may decrease during periods of 
sleep and movement, but increases during anxiety. Tremor occurs most often in younger 
patients. Another common initial symptom is the loss of finger dexterity, which impacts 
handwriting ability. Decreased movements, such as arm-swinging associated with 
walking, slowness of gait, reduced volume and monotonous speech are other early 
symptoms in PD.  
 In order for a diagnosis of PD to occur, cardinal signs and secondary signs are 
assessed (Leader & Leader, 2001). The first cardinal sign is tremor while resting. The 
next cardinal symptom is bradykinesia, or the slowness of initiation of voluntary 
movement. There is also a reduction in speed and increase in repetition of the movement. 
Another cardinal symptom is rigidity, or stiffness in the muscles. Degree of rigidity is an 
important indication of the level of disability for the individual. Another cardinal 
symptom is akinesia, or the reduction or absence of movement. The last cardinal sign is 
postural instability, which is a difficulty with balance and walking. Almost all patients 
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experience bradykinesia and rigidity, while tremor occurs in about 75% of individuals 
(Leader & Leader, 2001).  
 Secondary signs are not present during the early phases of PD, but will commonly 
occur during later stages. These secondary signs include cognitive decline, bradyphrenia 
(slow thinking), dysphonia (soft, low voice), micrographia (small size of and difficulty 
with handwriting), loss of facial expression, and dementia. Some psychiatric secondary 
signs include depression, sleep disturbances, and agitation. Symptoms related to the 
cranial nerve include decreased eye blinking, blurred vision, or dysphagia (difficulty in 
swallowing). Autonomic secondary symptoms include orthostatic hypotension, 
impotence, constipation, sweating, and urinary bladder dysfunction. There may also be 
sensory symptoms, such as cramps, pain, and olfactory dysfunction. Seborrhea, or 
excessive greasiness and scaliness of the skin might also occur.   
 Cardinal, or main symptoms are found in the majority of those with PD. One or 
more of the cardinal symptoms need to be present in order for a diagnosis of PD to occur. 
All cardinal and secondary symptoms may not necessarily exist in individuals with PD. 
In addition, there are individual differences with symptoms across the PD population. For 
example, there may be differences in the onset of the first symptom, the order and timing 
of onset of other symptoms, and severity of symptoms (Jahanshahi & Marsden, 2000). 
The symptoms may also fluctuate in severity according to time of day.  
 
Drug Treatment 
 
 The main goal of pharmacological treatment of PD is to improve symptoms and 
quality of life. Although drug treatment cannot alter the history of PD, it is intended to 
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treat symptoms and more specifically compensate for the deficit in dopamine levels in the 
brain.  
 It is debated at which time drug treatment should begin (Leader & Leader, 2001). 
Some researchers suggest that drug treatment should begin during the early phases of PD 
to provide an improvement for the individual. Others prefer to wait until motor 
complications begin. During the absence of drug treatment, psychological, occupational, 
financial, physiological, and nutritional support may be provided to individuals and their 
families as they prepare to face the challenges of the disease.  
 
Surgical Treatment 
 Research has led to great improvements in surgical techniques for PD.  Surgery 
may occur for those with advanced PD when drug therapy is no longer effective. In 
addition to L-dopa being the primary drug treatment for PD, multiple surgical procedures 
have been used over time to reduce symptoms of the disease.  
One early type of surgery for individuals with PD involved surgical lesions to 
attempt to reduce symptoms of PD. Thalamotomy was the most widely used treatment of 
this type and was particularly helpful in reducing tremor in PD. Pallidotomy is another 
type of lesioning surgery that has been used more recently to reduce tremor in PD 
patients (Côté, Sprinzeles, Elliott, & Kutscher, 2000). Deep brain stimulation (DBS) 
involves implanting electrodes in the brain to alleviate PD symptoms. The electrodes are 
attached by wires to a device under the skin in the chest (much like a heart pacemaker) 
that sends electrical impulses to specific parts of the brain (Côté et al., 2000).  
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Finally, this study focused specifically on a type of neural transplant surgery, or 
fetal tissue transplantation for those with PD. The purpose of this surgery was to implant 
aborted fetal tissue into the caudate and putamen areas of the brain where it was hoped 
the new tissue would grow and the new neurons would start producing dopamine (Côté, 
et al., 2000). Unblinded clinical trials have demonstrated that fetal tissue transplantation 
can improve some symptoms of PD, and that transplanted dopamine neurons may survive 
(Olanow, Kordower, & Freeman, 1996, Lindvall & Hagell, 2000, Freed et al., 2001, 
Redmond Jr., 2002, Betchen & Kaplitt, 2003, Björklund et al., 2003). A limited amount 
of research exists on how fetal tissue transplantation impacts quality of life (McRae et al., 
2004) in those with PD.  
 
Quality of Life 
 
Although there are very challenging physical symptoms of the disease, PD also 
affects the physical, social, and emotional aspects of life. The term quality of life (QoL) 
can include many psychosocial domains. As used in this study, QoL will be used to 
describe three broad areas: Physical, Emotional, and Social functioning.  
The domain of Physical functioning includes the physical aspects of the disease 
from the patient’s perspective. It considers assessing the ability to perform various 
activities on and off medications, or when the patient is “best” and “worst.” Standard 
activities of daily living and stage of disease are also typically included in this domain. 
Emotional functioning is a broad area that includes depression, reduced self-
esteem, anxiety, and stress. It is not surprising that individuals with PD may become 
depressed from the physical symptoms alone. It is also possible for depression to be a 
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side effect of certain drugs. Psychologically, depression may also result from changes in 
lifestyle and relationships. Anxiety is often common in PD, perhaps resulting from the 
uncertainties of the disease, or as a result of the disease process itself.  
Physical symptoms and motor deficits may become exacerbated by stress. This is 
because adrenaline, the hormone released when responding to stress, is metabolized by 
dopamine (Leader & Leader, 2001). Becoming withdrawn after a diagnosis of PD could 
affect relationships with others, which may ultimately affect self-esteem. Also, sexual 
problems may result from PD, the drug treatment, or depression. This may greatly impact 
self-esteem. Other influences on self-esteem may include dwelling on problems, concern 
over appearance, forgiveness of self and others, and unrealistic expectations of 
improvement with the disease (Leader & Leader, 2001).  
Social functioning is affected in PD patients when movement becomes more 
difficult and people become more isolated. As symptoms increase, patients find 
interaction with others becomes more difficult. For example, developing a soft voice, not 
being able to write, and gradually thinking more slowly all affect abilities to participate in 
social situations.  
 
Statement of Problem 
While there is little research on the effectiveness of fetal tissue transplantation 
surgery as a treatment for PD, there is even less literature on long-term effects of this 
treatment. This study examined the longitudinal course of the disease and progress since 
the surgery of the patients who participated in a fetal transplant surgery trial beginning in 
1995. Specifically, the study focused on the QoL aspects of functioning previously 
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described. This investigation makes a unique contribution to the literature by describing 
the status of patients who received the implant 10 to 12 years after surgery.  
Participants were part of a parent study (Freed et al., 2001) that determined the 
effectiveness of fetal tissue transplantation. In the parent study, 40 individuals were 
assessed at Columbia-Presbyterian Medical Center (CPMC) in New York prior to 
surgery, and at four, eight, and 12 months after surgery. Twenty participants were 
randomly assigned to receive the fetal tissue transplantation procedure, while the other 20 
participants received a sham surgery with the understanding that they could receive the 
fetal tissue transplantation procedure at a later time. Patients and medical staff were blind 
to the type of procedure category participants were assigned until 13 months following 
the surgery. The purpose of the study was to assess whether participants who received the 
fetal tissue transplantation procedure improved significantly more than those who 
received the sham surgery, or placebo. 
Participants were asked to complete questionnaires assessing QoL immediately 
following medical evaluations at CPMC (McRae et al., 2004). In addition to QoL data 
collected before surgery, participants were assessed at four, eight, and 12 months after 
surgery before the blind was lifted. The purpose of the QoL study was to determine if 
there were differences in QoL when comparing those who received the fetal tissue 
transplantation procedure to those who received the sham surgery (McRae et al., 2004).  
In the present study, current data on QoL were compared with baseline, one-year, 
and two-year data on QoL from the original study (McRae et al., 2004). This study 
assessed longitudinal changes in QoL that occurred over time.  
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Research Questions 
 
1. What is the trajectory of change in QoL over time for the baseline, one-year, two-
year, and current long-term follow-up assessment? Analyses were performed 
separately on the three original domains of QoL: physical functioning, emotional 
functioning, and social functioning. 
2. Was there any change in personality based on results of the NEO-FFI for the 
baseline, one-year, two-year, and current long-term follow-up assessment? 
 
Limitations of the Study 
 
 Several limitations exist in the present study. First, the sample size is small 
because it includes only the persons from the original study who participated in the QoL 
portion of the investigation (n = 30). Of that number, some participants in the original 
sham surgery group did not receive the transplant, some participants had passed away, 
while others were either not able to be located due to outdated contact information or 
were not interested in participating in the current study. The total number of participants 
who were involved in the present study was small (n = 11).  
 Second, the results from this study cannot be generalized to other individuals with 
PD. This was a very unique study that involved experimental surgery and included the 
condition of sham brain surgery. In addition, the double-blind lasted more than one year. 
Individuals who volunteered for this investigation were truly pioneers and the results of 
the study provided important information about who received the best results from the 
surgery and how long the effects have lasted.   
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Summary 
 
Chapter One presented an introductory synopsis of PD, including the physiology, 
onset, symptoms, drug and surgical treatment, and QoL. In Chapter Two, a review of the 
literature will present more detailed information on PD, drug treatments, surgical 
interventions, fetal tissue transplantation, long-term progression of PD, and QoL.  
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Chapter Two
Literature Review 
 
Introduction 
 
Chapter Two provides a literature review on various aspects of PD. Topics 
include a more extensive introduction to PD, additional information on drug treatments 
and surgical interventions, with a focus on fetal tissue transplantation, long-term 
progression of PD, and QoL.  
The literature reviewed in this chapter was retrieved in numerous ways. First, a 
computer search using the database MEDLINE was used to identify literature pertaining 
to this study. Search topics included QoL, surgical treatment of PD, fetal tissue 
transplantation surgery, drug treatment of PD, and history of PD. A secondary search 
utilized the databases Academic Search Premier, PsycINFO, and PsycARTICLES. 
Search topics included QoL, PD, and treatment of PD. Books were located from libraries 
that included information on PD and QoL. In addition, authors and titles were identified 
from reference lists that were relevant to the study.  
 
Definition of PD 
 
Since its original description by James Parkinson, PD has been considered the 
prototypic movement disorder (Rascol et al., 2003). PD is a degenerative neurological 
disorder that has a considerable impact on the physical, emotional, and social aspects of 
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patients’ lives. A diagnosis of PD generally relies on the observation of the principal 
symptoms: tremor, rigidity, balance impairment or postural instability, bradykinesia 
(slowness of movement), and dyskinesia (abnormal involuntary movements and 
postures). Although patients may have different levels of these motor symptoms, patients 
are typically diagnosed with PD when there is a presence of one or more of these 
symptoms (Stacey & Jankovic, 1992).  
PD is primarily a movement disorder; however, it also severely impacts the 
autonomic, cognitive, and psychiatric functions of individuals. The impairment on these 
“non-motor” systems can adversely harm individuals with PD while strongly impacting 
their QoL. Non-motor symptoms tend to be unresponsive to antiparkinsonian medication, 
and may even be worsened by this treatment. The cause of PD is unknown, but evidence 
has suggested that environmental and genetic factors may at least contribute to the cause 
of the disease (Guttmen, Kish, & Furukawa, 2003). PD is associated with a degeneration 
of nigrastriatal dopamine neurons in the brain, yet the degeneration may also impact other 
central and peripheral areas of the nervous system (Rascol et al., 2003). 
Progression of PD often includes an increase in difficulty with mobility, balance 
and speech, and non-motor symptoms, including cognitive decline and depression 
(Keränen et al., 2003). “Off” phases are periods of increased PD disability, while “on” 
phases are periods of little or no PD-related motor disability (Hagell et al., 2002).  
The disease affects 1% of the population over the age of 60 (Firbank, Burn, 
McKeith, & O’Brien, 2005). Although many important advances have led to a better 
understanding of the underlying pathophysiology of PD, no treatments have been 
developed which cure the disease (Guttmen et al., 2003). Because the presentation of PD 
13 
varies among patients, most clinicians follow the course of each patient and make 
decisions for treatment according to the individual needs of each person. 
According to Rascol et al. (2003), there are factors that contribute to optimal 
treatment of PD. Treatment should be efficacious in reducing PD symptoms while 
slowing down rate of disease progression and increasing life expectancy. Treatment 
should also work while limiting the development of adverse side effects. Finally, 
treatment should be cost effective while also being available to all patients, regardless of 
social or economic status.  
 
Drug Treatment of PD 
Levodopa (L-dopa) is the most effective medication for the treatment of PD 
symptoms. This medication acts as a replacement therapy for the dopamine deficiency 
caused by PD. All patients with PD will utilize L-dopa in their treatment at some time 
during the progression of the disease. L-dopa is most efficacious during the first years of 
treatment. This period of treatment is known as the L-dopa “honeymoon” (Rascol et al., 
2003). Long-term use of L-dopa and other pharmacological treatments results in a decline 
of effectiveness of the medications over time. Thus, the limitations of L-dopa become 
more prominent during the more advanced stages of PD. Some limitations of L-dopa 
include a lack of improvement for many disabling motor and non-motor PD symptoms, 
side effects, and the inability to stop the progression of PD (Rascol et al., 2003). 
The benefits of L-dopa may be outweighed by motor complications caused by the 
drug, including fluctuations and dyskinesias. The Parkinson Study Group (2004) 
designed a study to evaluate the effects of L-dopa on the progression of PD. In this study, 
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361 who never had received dopaminergic drugs were randomly assigned to placebo or 
L-dopa at 150, 300, or 600 mg/day for 40 weeks, which was then followed by a 2 week 
period off the drugs. Scores from the Unified Parkinson’s Disease Rating Scale (UPDRS) 
showed an increase (higher level of depression) in 7.8 points for the placebo group. The 
two lowest doses of L-dopa had an increase of 1.9 points, and there was a decrease in 1.4 
points for the highest dosage group. Freezing was observed in the placebo group, but 
dyskinesias were commonly found in the highest dosage group (The Parkinson Study 
Group, 2004). 
Jankovic (2006) stated that the emergence of dyskinesias due to L-dopa may be 
related to the shortening of L-dopa’s half-life in the striatum because the body with PD 
has an impaired ability to store the L-dopa due to the loss of dopamine terminals. Since 
this is occurring, there is less of a continuous delivery of L-dopa to the brain. The 
recommendations for reducing L-dopa induced dyskinesia is to reduce each dosage of L-
dopa, use drugs that are known to reduce dyskinesias, and to get surgery.   
 
Surgical Treatment of PD 
The ultimate decline of effectiveness of drug therapy has led to an exploration of 
alternative treatment for PD symptoms (Clarkson & Freed, 1999). Freed et al. (2001) 
reported that although L-dopa was the treatment of choice for years, motor fluctuations 
such as bradykinesia and hyperkinesias still developed in many patients with PD over 
time. No drug therapies have proven to effectively improve motor fluctuation for 
extended periods of time. Therefore, several types of surgery were developed as 
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alternative treatments of PD. These treatments include ablative surgeries, deep brain 
stimulation, gene therapy, and neural transplantation.  
 
Ablative Surgery  
            Surgical procedures were common for those with PD in the 1950s and '60s. When 
L-dopa was developed, surgery became a less popular treatment method. Researchers in 
Sweden and France started experimenting with surgery again during the 1980s, and 
American physicians did the same in the early 1990s (Cowley, Murr, Peyser, & Sawhill, 
2000). Before modern surgeries evolved, ablative surgeries were the popular method of 
surgery for PD. 
In ablative surgery, brain tissue affected by PD is located and then destroyed. The 
purpose of the procedure is to remove tissue that produces abnormal chemical or 
electrical impulses that will ultimately create tremors and dyskinesias. The two types of 
ablative surgery are thalamotomy and pallidotomy.  
The first type of ablative surgery that was used was thalamotomy.  During this 
surgical procedure, part of the thalamus is destroyed (Cowley et al., 2000). Thalamotomy 
is primarily used to eliminate tremors. During a thalamotomy procedure, part of the tissue 
in the globus pallidus is destroyed. Typically, pallidotomy is performed to eliminate 
uncontrolled dyskinesias. When surgery on both sides of the brain is performed, side 
effects such as weakness and slurred speech may occur. Therefore, one side of the brain 
is typically targeted in the operation (Cowley et al., 2000).  
Comparing research findings of thalamotomy and pallidotomy procedures is 
difficult because of the variation in the areas targeted, the surgical procedure, selection of 
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patients, and rating scales (Krack & Vercueil, 2001). Thalamotomy has been found to 
improve symptoms of dystonia, a condition where muscle contractions often cause 
twisting and repetitive movements. Some researchers have found that the amount and 
severity of complications, mainly speech disturbance, is at a lower rate after pallidotomy, 
rather than thalamotomy (Krack & Vercueil, 2001).  
 
Deep Brain Stimulation (DBS) 
Researchers have found that the subthalamic nucleus (STN) and the globus 
pallidum internus (GPi) areas of the brain play an active role in the symptoms of PD 
(Jankovic, 2006). During deep brain stimulation (DBS) surgery, electrodes are implanted 
in the brain (Krack et al., 2003). A few days after implantation of the electrodes, a 
generator or pacemaker is implanted in the chest and adjusted to the correct settings. The 
areas of the brain with electrodes are then targeted with high frequency stimulation to 
reduce PD symptoms. High-frequency DBS simulates the effect of a lesion without 
deliberately damaging the brain (The Deep-Brain Stimulation for Parkinson's Disease 
Study Group, 2001).                                                    
Several studies have shown that DBS of the GPi and STN can improve symptoms 
of PD and prolong the “on” time (Jankovic, 2006). In a double-blind study of 143 
patients with advanced PD, DBS was performed. Results indicated that motor scores of 
the treatment group improved by 49% when compared to the group who did not receive 
DBS. Six months after receiving the procedure, “on” time without dyskinesias for those 
receiving DBS of the STN had improved from 27 to 74 percent. Those who had received 
DBS of the GPi had an improvement from 28 to 64 percent (Jankovic, 2006). Adverse 
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side effects included intracranial hemorrhage in seven participants and lead explantation 
in two patients. Speech did not improve over time. The authors concluded that STN DBS 
is not better than L-dopa, but that it does improve motor complications related to taking 
L-dopa, and dyskinesias and off-period dystonia (Jankovic, 2006).   
Krack et al. (2003) studied 49 patients with PD for 5 years following DBS. The 
participants were assessed at 1, 3, and 5 years with L-dopa (on medication) and without 
L-dopa. After five years, the researchers found significant improvement in motor 
symptoms and dystonia while off L-dopa, and in dyskinesia while on medication. The 
study did not include a control group. Consistent with the long-term progression of PD, 
the researchers found that there was an increase in akinesia and freezing of gait, and a 
decline in speech, postural stability, and cognitive functioning (Krack et al., 2003).  
 
Gene Therapy 
 Gene therapy has long been considered as a treatment option for PD. Gene 
therapy includes adding a gene into cells with the goal being to change the functioning of 
these cells (Betchen & Kaplitt, 2003). A second type of gene therapy includes placing the 
gene under a regulatory control that will initiate a production of the gene in cell locations 
that do not normally reproduce the gene (Betchen & Kaplitt, 2003). The ultimate goal of 
these gene therapy procedures is to genetically change the functioning of neurons in the 
brain. Research into gene therapy is ongoing, but science in this area has not progressed 
to the point of applying the research to human candidates.                                                                            
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Neural Transplantation 
           During the neural transplantation procedure for PD, the goal is to transplant or 
replace the dopamine producing neurons of the substantia nigra that are impaired 
(Betchen & Kaplitt, 2003). Examples of neural transplantation include stem cell 
transplantation and fetal tissue transplantation.  
 
Neural Transplantation: Stem Cell Transplantation Surgery 
 
Stem cells are immature cells that have an ability to self-renew, depending on site 
of origination. They also have the ability to differentiate into multiple cell types 
(Lindvall, Kokaia, & Martinez-Serrano, 2004). Even though animal studies have shown 
that stem cells survive four times longer than fetal cells, only 22% of grafted stem cells in 
one study survived (Kawasaki et al., 2000). A small fraction of the 22% of cells actually 
produced dopamine.  
The results of randomized trials of implanting stem cells for those suffering from 
PD have generally been disappointing (Rice, Halfpenny, & Scolding, 2003). If the 
procedure were proven to be an effective form of treatment for PD, there are certain 
criteria that should be further explored. For example, there needs to be a more clear 
definition of the method for selecting patients appropriate for this type of therapy. Also, 
there needs to be an improvement in the efficacy of grafts. There is no evidence that 
stem-cell neurons will create a more pronounced improvement over fetal neuron grafts. 
Lastly, there needs to be more research on adverse side effects on this type of therapy 
(Lindvall et al., 2004). Stem cell therapy is considered a promising yet controversial type 
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of treatment for neurodegenerative disorders. Social issues surrounding this practice 
influence the pace of scientific discovery on the efficacy of this procedure.  
 
Neural Transplantation: Fetal Tissue Transplantation Surgery 
 
It was believed that fetal tissue transplantation could improve motor fluctuation in 
patients where the levodopa had become inefficient in treating the disease (Freed et al., 
2001). Clinical trials in the mid to late 1980’s showed that fetal tissue transplantation 
surgery had the ability to reduce some PD symptoms, and that transplanted neurons can 
survive (Freed et al., 2001). Because the present study is based on fetal tissue 
transplantation surgery, the focus of the remainder of this introduction and the literature 
review will be specifically on this treatment.  
 Advances in interventions in PD treatment depend on technology and expertise, 
thus making them costly. In order for these interventions to gain acceptance in the 
scientific community, it is important that they demonstrate long-term effectiveness 
beyond the successes of current treatments for PD. Effective treatment of PD will ideally 
address the nature of PD symptoms themselves, but also the social and emotional 
consequences of the disease (Hjelmgren et al., 2006).  
Since 1988, patients with PD have been involved in clinical trials investigating 
the efficacy of neural transplantation of fetal tissue into the brains of those affected with 
the disorder (Clarkson & Freed, 1999). Fetal tissue transplantation surgery has been used 
as an experimental procedure to reduce symptoms of PD (Bethche, & Kaplitt, 2003; 
Freed, Greene, & Breeze, 2001). This type of surgery includes the stereotactic 
implantation of human embryonic dopamine neurons into brain tissue of those suffering 
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from PD (Freed et al., 2001). The premise of this surgery is based on the belief that 
dopamine-producing tissue from fetuses within a six to ten week gestation period will 
produce positive results for the recipient. This includes reinnervating the striatum by 
establishing dendritic connections with the already existing dopamine receptors (Freed et 
al., 2001).  
The efficacy of fetal tissue transplantation surgery for reducing the symptoms in 
individuals with PD has been investigated (Freed et al., 1992; Clarkson & Freed, 1999; 
Clarkson, 2001). Freed et al. (1992) initially used the implantation of dopamine cells in 
seven individuals with PD. Improvements in motor symptoms and functioning were 
reported following the procedure. However, questions remained regarding the 
experimental nature of the procedure and the influence of a placebo effect on the positive 
outcome of the surgeries (i.e., placebo effect and a lack of a comparison group). Clarkson 
(2001) reviewed the fetal tissue transplantation literature, and summarized that even 
though this treatment has led to a reduction in levodopa administration and an 
improvement in motor skills, several questions need to be addressed regarding this 
procedure before it can become more widely accepted.  
Clarkson and Freed (1999) found that the transplantation resulted in patients 
requiring less L-dopa administration and a moderate improvement in motor skills. 
Olanow et al. (2003) studied 34 patients with PD during a 24-month double-blind, 
placebo-controlled trial of fetal transplantation. There was no significant improvement in 
the treatment group when compared to the control group. They did find a significant 
benefit in the transplant when the patients had less severe motor symptoms at baseline. 
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This result suggests that the procedure prevented further deterioration of motor 
symptoms, rather than an improvement in motor symptoms (Olanow et al., 2003).  
Freed et al. (2001) studied patients with PD who received transplantation of 
human embryonic dopamine neurons. The results indicated that the neural tissue survived 
in those who had a severe form of PD. It was noted that more clinical benefit was found 
in younger patients than older patients.  
 
Results of the Parent Fetal Tissue Transplantation Study 
 
Freed et al. (2001) conducted a double-blind sham-controlled trial to investigate 
the effectiveness of fetal tissue transplantation (human embryonic dopamine neurons) 
into the brains of those with advanced PD. Specifically, the authors investigated the 
effects of the surgery across the dimensions of physical and neurological functioning. 
The purpose of the study was to determine whether those in the transplant group 
experienced more improvement than those in the sham group over the one year period of 
the double-blind.  
The fetal transplantation surgery that occurred in the parent study (Freed et al., 
2001) included the following procedural steps. All 40 participants had a stereotactic 
frame attached to their head for magnetic resonance imaging for the purpose of deciding 
the location of the needle tracks for the tissue implantation (McRae et al., 2004). Four 
burr holes were drilled bilaterally into the foreheads for the needles while the participants 
were awake. Scalp incisions and twist drill holes occurred while the participants were 
under local anesthesia. Both the transplant and sham participants received the same 
preoperative evaluation, sedation, and pain control. Implants into the putamen with 
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embryonic mesencephalic tissue containing dopamine neurons occurred for those in the 
transplant group. Those receiving the sham surgery had needles that were empty and did 
not penetrate the brain (McRae et al., 2004). Additional information about the surgical 
procedure can be found in the parent study article by Freed et al. (2001).   
Participants included a volunteer sample of 40 individuals with idiopathic PD; 20 
persons received the transplant and 20 persons received the sham surgery with the option 
of receiving the transplant after one year when the blind was lifted. Thirty participants 
volunteered for the QoL study. Of these 30 participants, 12 received the transplant, and 
18 received the sham surgery. Assessment of QoL was done at baseline, four, eight, and 
12 months after surgery (McRae et al., 2004).  
 
Results of the Original QoL Study 
McRae et al. (2004) investigated QoL and medical outcomes of the transplant and 
sham surgery groups at 12 months before the double-blind was lifted. In addition, the 
QoL study examined perceived treatment groups at four, eight, and 12 months in terms of 
QoL and medical outcomes. The investigators found only two changes over time among 
those who received the transplant. However, according to the participants’ perceived 
treatment, there were many changes within the one year of the double-blind condition. 
Participants who believed they had received the transplant reported more positive results 
regarding QoL than those who thought they had received the sham surgery. The authors 
also included ratings by the medical staff, which produced the same result. Results 
indicated that the placebo effect was very strong in this placebo-controlled surgical trial.   
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Research regarding fetal tissue transplantation as a treatment for the improvement 
of PD symptoms has been inconclusive. Investigation of this intervention was 
discontinued at the end of the federal funding by the National Institute of Health in 2001. 
 
Longitudinal Follow-up of 10-12 Years After Original Study 
In the present study the longitudinal effects of fetal tissue transplantation surgery 
on QoL factors for patients suffering from PD were investigated. The participants were 
the same individuals who were involved in the original QoL study (McRae et al., 2004). 
These patients received the surgery between 1995 and 1998 and were followed until 2000 
(Freed et al., 2001). Those participants receiving the sham surgery were later offered the 
transplantation surgery, and were, therefore, potential candidates for this follow-up study.  
The purpose of this study was to investigate the long-term effects of the fetal 
transplant surgery on these individuals, specifically looking at QoL. Present QoL and 
changes over time in terms of QoL were investigated. Measures focused on the three 
dimensions of QoL: Physical, Emotional, and Social functioning. These data were 
collected 10-12 years after the surgery took place to determine longitudinal effects of the 
transplant. The current data were compared to the baseline, one-year, and two-year data 
from the original study (McRae et al., 2004). By doing this comparison, changes over 
time were investigated.  
 
Importance of Study 
 
Unique Sample 
 
Longitudinal studies pertaining to the topic of fetal tissue transplantation and PD 
have not been done, and a follow-up investigation will be important to study the changes 
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in QoL that these participants have experienced over time. A longitudinal investigation of 
the effects of this surgery will be an important contribution to this field of literature. 
 
Quality of Life 
 
Quality of life (QoL), as defined in this study, includes three aspects: Physical, 
Emotional, and Social functioning. By studying QoL, there is an intimate look at how the 
surgery has impacted the participants on an everyday basis. Components of QoL include 
how participants view their health, performance of daily activities, severity of symptoms, 
description of feelings, levels of stress, level of social support, and interaction with 
others. An important method in promoting patients’ point of view in clinical practice and 
decision processes is discovered by investigating QoL (Bergland & Narum, 2007).  
QoL more specifically may describe people’s sense of well-being, purpose in life, 
autonomy, identification with certain roles, and ability to participate in significant 
relationships. Factors of QoL that face people with PD may also include symptoms and 
needs of a changing physical body, difficulty with communication, unpredictability of the 
disease, and a changing sense of identity (Koplas et al., 1999). Individuals with a chronic 
disease like PD may also struggle with their sense of control. Perception of control is also 
related to sense of well-being and adjustment to having PD. One study found that the 
patient’s perceived control of symptoms of PD was significantly related to patient and 
caregiver well-being (Wallhagen & Brod, 1997). Koplas et al. (1999) found that PD 
patients’ beliefs that their behavior could influence the outcome of personal situations 
and life events was a significant predictor of QoL. This perceived control factor was a 
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large influence on QoL, even though the participants may have been experiencing 
depression and physical disabilities.  
Knowledge of QoL and its influence is important when managing a serious 
disease like PD. Although there is no known cure for PD, there is a relatively normal life 
expectancy with modern treatments available (The Global Parkinson’s Disease [GPDS] 
Steering Committee, 2001). Both PD symptoms and medications greatly influence QoL. 
Depression and cognitive impairment have also been found to be significant predictors of 
QoL when dealing with PD (GPDS, 2001).   
Reuther et al. (2007) assessed QoL in 145 individuals with PD during a 12 month 
period by using a non-disease specific and also disease-specific QoL scales. Significant 
changes in QoL were found in the disease-specific QoL scales, but not the general 
assessments. The disease-specific scales were sensitive to changes in QoL, revealing that 
PD considerably affected QoL over the 12-month period. Specifically, the presence of 
depression, motor complications, falls and gait instability, type of PD, and cognitive 
impairment were identified as predictors of QoL. The authors concluded that future 
studies are needed to specifically evaluate QoL changes over long periods of time.   
Kuopio, Marttila, Helenius, Toivonen, and Rinne (2000) examined QoL in 228 
patients with PD. They investigated the associations of age, age at onset, duration, 
clinical stage, depression, and dementia. The authors found that depression was more 
commonly found among female patients with PD. They also found that as PD progressed, 
there was a decrease in QoL on the dimensions of Physical functioning, role limitations, 
and Social functioning. Longer duration of illness was related to diminished Social 
functioning. The older the patient was at the onset of the disease, the lower the QoL in 
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terms of vitality. Mental health status was lower when the age of onset was younger. 
Older age with the disease was related to a lower QoL only on physical functioning.  
 
Quality of Life and Depression 
Due to diagnostic and selection criteria, there are varying degrees of reported 
prevalence of depression in those with PD. Based on a general consensus, depression 
affects approximately 40% of those with PD and greatly impacts QoL (Rascol et al., 
2003). There is not a linear relationship between degree of depression and severity of PD 
symptoms. Depression is more commonly found in patients who are at the initial and 
later stages of PD (Cummings & Masterman, 1999). 
Depression may occur more often in those with PD than among the general 
population. Early onset of PD symptoms (before 55 years) and a family history of PD are 
common risk factors for depression in PD. There may be a positive clinical response to 
antidepressant medication among those with PD (Cummings & Masterman, 1999). 
Neurologists of the Parkinson’s Study Groups (PSG) care for over 20,000 patients with 
PD. A survey 49 neurologists revealed that only 26% of PD patients were receiving 
antidepressant medication for depression (Cummings & Masterman, 1999). Controlled 
trials to better understand pharmacological treatment of depression for those with PD 
have not yet occurred (Guttman et al., 2003).  
Other psychiatric symptoms may also occur in PD patients. For example, drug 
induced psychosis may be a management problem and could potentially create difficulty 
for families providing care to those with PD at home. Other symptoms that could develop 
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include visual hallucinations, paranoia, and other psychotic symptoms (Guttman et al., 
2003). 
 
Quality of Life and Anxiety 
Similar to those without PD, anxiety has a negative effect on QoL for those with 
PD. Anxiety has been related to increased psychosocial disability (e.g., activities of daily 
living) and decreased sense of emotional well-being in those suffering from PD. Nearly 
40% of individuals with PD meet a diagnosis for anxiety disorders (e.g., generalized 
anxiety disorder, panic disorder, and social phobia) in the Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition (Menza & Dobkin, 2005).  
 Individuals with PD often experience anxiety prior to the onset of PD. The 
anxiety often is comorbid with depression and becomes more severe when motor 
fluctuations develop. Those with PD most likely also experience anxiety due to the 
neurochemical and degenerative changes that occur within PD, in addition to the 
debilitating progression of PD. Anxiety has been found to be a stronger predictor of QoL 
than either physical symptoms or major depressive disorder in the areas of interpersonal 
interaction quality, health satisfaction, and overall well-being (Menza & Dobkin, 2005).  
 Studies have shown that there is often a comorbidity of depression and anxiety for 
those with PD. The impact of comorbid anxiety and depression on treatment and 
progression of PD remains unknown. Some have stated that comorbid depression and 
anxiety with PD is correlated with greater chronicity, treatment resistance, and a worse 
prognosis (Brooks & Doder, 2001). Research has shown that there was an increased 
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comorbidity of non-motor symptoms such as depression and anxiety connected with 
more severity of PD symptoms (Shulman, Taback, Rabinstein, & Weiner, 2002).  
 
 Quality of Life and Cognitive Decline 
 
 Although many symptoms of PD are related to physical ability, the disease also 
affects intellectual functioning. Most people with PD will be affected by cognitive 
impairment. Symptoms of cognitive decline include attention difficulties, concentration, 
problem solving, and memory. These areas of decline often are reported in relation to 
paying attention at work, difficulty handling more than one project at a time, difficulty 
with planning and organizing responsibilities at home, and problems with completing 
tasks after they have begun (Bassett, 2005).  
 A significant number of people will develop dementia during the course of PD. A 
recent study suggested that 20% to 40% of those with PD will eventually develop 
dementia, with a 10% incidence rate per year (Aarsland, Andersen, Larsen, Lolk, & 
Kragh-Sorensen, 2003). Menza and Dobkin (2005) stated there is a relationship between 
anxiety and cognitive impairment among both non-PD and PD individuals.  
 
Important Patient Data on Quality of Life 
 
It was important to assess how QoL has improved, worsened, or stayed the same 
for individuals who received the fetal tissue transplant surgery. The data gathered were 
compared to data from baseline, one-year, and two-years after surgery from the original 
study (McRae et al., 2004) to determine how QoL had changed over time. This study is 
important because it provided information related to whether or not this procedure was 
viable or was helpful for any of the previous participants. Results of this project will 
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contribute to the body of knowledge related to which types of patients, if any, might 
potentially benefit most from the surgery. The study also determined the length of time 
that the effects of surgery have lasted. Thus, results of the investigation provided 
information on whether the fetal tissue transplantation surgery is a useful procedure to 
pursue, and how it might be a credible alternative treatment for some people.  
 
Guidelines for Future Transplant Studies  
 
The results of this study were valuable in gaining longitudinal data on the effects 
of fetal tissue transplantation for PD. Another benefit of this study is that it makes 
important inferences regarding the effectiveness of the surgical procedure. This includes 
how the patients responded to the surgery, and how well the surgery worked for each 
patient. By gathering these data, it is hoped that the results indicated who has benefited 
the most, the least, or not at all from the transplant surgery. Results may suggest selection 
criteria for those with PD who may consider this type of surgical treatment. 
 
Longitudinal Research and Progression of PD 
Knowledge about the expected progression and outcome of treatment are 
beneficial for the knowledge of any disease. Primary goals of health psychology include a 
thorough description and explanation of changes over time with disease (Hagell et al., 
2002). Longitudinal studies can reveal the comprehensive evidence of progress, 
stagnation, or decline (Hagell et al., 2002). By studying longitudinal data, researchers can 
better understand which factors contribute to the improvement or progression of a disease 
(Rosser & Dunnett, 2003). This type of research may also be valuable in determining 
which aspects of disease are specifically improving or declining over time. This 
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knowledge also contributes to a better facilitation for treatment and long-term change. 
Long-term follow-up studies provide an increase in knowledge that may ultimately 
contribute to the planning of rehabilitation for disease.  
 
Long-Term Change in Parkinson’s Disease 
PD is a degenerative neurological disorder that includes a slow deterioration in 
the QoL of those afflicted with the disorder. It is a progressive condition that worsens 
over time. Although the rate of nigral cell death is not known, neuroimaging techniques 
estimate that the rate of cell death occurs approximately 10% every year (Rascol et al., 
2003).  
Longitudinal studies of PD have focused on cognitive, medical, and functional 
changes over time. Even without dementia, PD can have a harmful impact on cognitive 
decline. Azuma et al. (2003) reported that significant cognitive impairment may be 
observed for eight years and longer, but cognitive decline is slower over briefer periods 
of time, such as one year. Comparing control elderly individuals to those with PD can 
demonstrate deficits in relative performance, but longitudinal data can provide 
knowledge on how cognitive processes change over long periods of time (Azuma et al., 
2003).  
Jacobs et al. (1995) studied the factors that predict cognitive decline in individuals 
with PD. Neuropsychological tests were administered to 111 PD patients who did not 
have dementia. There were 23 patients who were diagnosed with dementia at follow-up 
testing (2.7 years). Factors associated with dementia included age, Unified Parkinson’s 
Disease Rating Scale (UPDRS) scores, and depression. Mahieux et al. (1998) found that 
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among the 81 non-demented PD patients, 19 were diagnosed with dementia at follow-up 
testing. The researchers found that Picture Completion from the WAIS-R and age of 
disease onset were significantly related to dementia. Azuma et al. (2003) tested PD 
patients twice across two years and found cognitive decline across disease progression.  
One reason to study the longitudinal effects of fetal tissue transplantation on PD is 
to differentiate the results compared to the normal progression of PD without this surgical 
procedure. Rosser and Dunnett (2003) expected the benefits of fetal tissue transplantation 
to not be detectable in PD patients for at least a year, based on animal studies and current 
research on PD patients. Piccini et al. (1999) reported that PD studies show that it may 
take subsequent years post-neural transplantation surgery to see the beneficial effects.  
Hagell et al. (2002) studied dyskinesias following fetal tissue transplantation in 
Parkinson’s disease. The authors retrospectively studied 14 patients 11 years after 
receiving fetal tissue transplantation. They found that dyskinesias (abnormal involuntary 
movements and postures) increased during postoperative off phases, but were generally 
of mild to moderate severity. They concluded that off-phase dyskinesias probably did not 
result from excessive growth of grafted dopaminergic neurons. 
Management of PD is intended to improve the QoL of patients. Drug therapy is 
only one of the options for the management of PD. Different medical therapies are 
utilized according to the symptoms and stages of patients’ disease. The primary goal of 
management is for the patient to have as close to normal functioning as possible with the 
absence of side effects from the therapy (Rascol et al., 2003).  
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Quality of Life: The Importance of the Patient’s View in Clinical Trials 
It is important to include patients’ perspectives of the impact of PD and its 
treatment on their QoL. Patients have been involved in evaluating different aspect of 
health care at an increasing rate (Staniszewska, 1999). Traditional medical ways of 
collecting health information, such as laboratory tests, can be limiting in the type of 
information provided. For example, a radiological test will not give information 
regarding patients’ reactions or emotions about their illness. Patient perspectives, or QoL 
information is now considered to be central in the treatment of chronic disease 
(Staniszerska, 1999).  
QoL encompasses a person’s physical health, psychological state, personal 
beliefs, social relationships, and relation to features in the environment (Calvert & 
Freemantle, 2003). It also includes the manner in which disease and treatment affect 
emotional, physical, and social well-being. QoL serves as a subjective indication of the 
individual’s perception of the impact of disease and treatment on health status (Calvert & 
Freemantle, 2003).  
Research on disease has mainly focused on symptoms, survival, and treatment, for 
example. Although these outcomes play an instrumental role in understanding chronic 
disease, it is also important to better understand the effect the disease has on everyday 
activities, mobility, and relationships. QoL measures have been developed to assess 
patients’ perspectives of their health and well-being on a subjective level (Staniszewska, 
1999). Understanding QoL can enable physicians and those on the treatment team to gain 
knowledge of how patients are coping with the progression of the disease. Information 
from patients can also provide clinicians with knowledge that can help other patients 
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dealing with the same issues related to treatment (Calvert & Freemantle, 2003). QoL as a 
component of health treatment has been emphasized in studies where patients and 
clinicians provide different interpretations of care, indicating that ideas from both sides 
should be considered in treatment. Improving QoL is vital when dealing with a chronic 
illness like PD, a disease that cannot be cured, but must be endured for years.  
A long-term follow-up to treatment that is focused on QoL of the patient should 
explore the patient’s values and treatment effects that are meaningful to the individual. In 
addition, it is important to examine the patient’s understanding of PD, evaluations, 
treatment decisions, and possible outcomes (Sweet, 2004).  The measure of QoL should 
allow each participant to provide their personal assessment of change over time 
(Paterson, 2004). These subjective health questions enable patients to contribute to 
evaluating outcome, and to have the importance of helping follow-up research findings to 
be more patient-centered and relevant (Paterson, 2004). It is rare for follow-up studies to 
capture patients’ perspectives of change. However, it is the aim of this study to do just 
that. 
Summary 
Chapter Two provided a literature review on detailed information on PD, drug 
treatments, surgical interventions, fetal tissue transplantation, long-term progression of 
PD, and QoL with PD.  
PD is a chronic and life-altering disorder that affects many individuals, mainly 
during the later stages in their lives. Although much literature exists on the nature of PD, 
and drug and surgical treatments, there is minimal research on the QoL for these 
individuals, especially over an extended period of time. More specifically, little is known 
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about the QoL of those who received fetal tissue transplantation surgery as a method to 
reduce PD symptoms.  
The present study was designed to investigate the QoL for participants who 
received fetal tissue transplantation in the parent study 10-12 years ago. The study 
assessed how individuals’ Physical, Emotional, and Social well-being has changed over 
time since the initial surgery.  
Chapter Three will discuss the method and procedure used in this study while 
investigating longitudinal changes in QoL and PD.  
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Chapter Three
Method 
 
 
Chapter Three describes the methodology used in the present study. This chapter 
includes information on the participants, measures, and data analyses.  
 
Participants in Parent Parkinson’s Disease Study 
 
Patients were recruited for the parent study (Freed et al., 2001) through contacts 
with neurologists across the United States and Canada, and in consultation with Dr. 
Stanley Fahn (Columbia Presbyterian Medical Center; CPMC) and Dr. Curt Freed 
(University of Colorado Health Sciences Center; UCHSC). Patients were assessed and 
evaluated two times for three or four days at each time before being accepted into the 
parent study. For the parent study, there were 40 patients who were accepted as 
participants.  
 
Participants in Original Quality of Life Study and Current Investigation 
 Of the 40 patients in the parent study, 30 of them agreed to participate in the 
original QoL study. Of these 30 participants from the original study, updated contact 
information was identified for 14 people. For the remaining 16 participants, either contact 
information was unable to be found, some people refused to participate, or some 
participants had passed away. Of the 14 participants, 11 of them agreed to participate in 
the current investigation. Demographic information for the participants involved in the 
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current study is presented in Table 1. For the demographic variables of age, duration of 
disease, and duration of education completed, data were collected from the baseline 
assessment. For the demographic variables of current living situation, marital status, 
currently paid for employment, and volunteer work, data were collected from the current 
assessment. The demographic variables gender and ethnicity remained the same. 
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 Table 1 
Demographic Information of Participants in the Current Investigation 
Demographic Variables Demographic Information   
Gender: Male 
              Female 
3 
8 
Age (from baseline assessment)  
             Mean years 
             Range 
 
51.91 ± 7.53 
40 - 62 
Duration of disease (from baseline assessment)  
             Mean years 
             Range 
 
13.64 ± 4.95 
8 - 25 
Ethnicity - number 
             Native American 
             African American 
             Caucasian 
             Hispanic 
             Asian 
             Other 
 
0 
0 
11 
0 
0 
0 
Duration of education completed (from baseline 
assessment)  
             Mean years 
             Range 
 
 
16.82 ± 2.27 
13 - 19 
Current living situation - number (from current 
assessment) 
             Living with family 
             Living with friend or roommate 
             Living alone 
             Living in residential setting 
 
 
9 
0 
1 
1 
Marital Status - number (from current assessment) 
             Never been married 
             Married or living with partner 
             Separated or divorced 
             Widowed 
 
0 
9 
1 
1 
Currently paid for employment (from current 
assessment) 
              No 
              Part-time 
              Full-time 
 
 
7 
3 
1 
Volunteer work (from current assessment) 
              No 
              Yes 
              Previously, but not currently 
 
3 
6 
2 
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Inclusion and Exclusion Criteria 
 
 There were several inclusion criteria that needed to be met in order for 
participants to be accepted into the parent study (Freed et al., 2001). The participants 
needed to be in an advanced stage of idiopathic PD for at least seven years with some 
responsiveness to L-dopa. Another criteria was that there needed to be a continued yet 
reduced improvement from the L-dopa treatment. The patients had previously tried other 
forms of medical treatment, and were now medically appropriate to undergo transplant 
surgery with certification by their physicians. There was evidence of chronic symptoms, 
such as “off” periods and dyskinesias or freezing which were not controlled by dopamine 
medication. The participants were willing to participate in ongoing research, and were 
able to pay for expenses not covered by the initial NIH grant for the parent and original 
studies. In addition, the participants fell in the age range of 20 to 75 years, and had no 
serious depression, hallucinations, or cognitive impairment. Finally, the participants had 
normal MRI brain scans within the last 18 months of the parent and original studies, and 
their PET scans were indicative of idiopathic PD (Freed et al., 2001).  
 Exclusion criteria for participants in the parent and original studies included 
severe or moderately severe depression, gross signs of dementia, and previous brain 
surgery or injury. Additionally, participants could not show evidence of diabetes, severe 
cardiopulmonary disease, other severe medical conditions, or MRI evidence of a 
cerebrovascular disease. Patients who could not get medical clearance from their 
physicians were not accepted to participate in the transplant study (Freed et al., 2001).  
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Procedure 
The same participants accepted into the parent study who also then participated in 
the QoL study were asked to participate in the present investigation. Contact information 
(i.e., phone number, address) of participants was updated by contacting patients over the 
telephone, and looking up information on the internet. Participants were contacted by this 
researcher over the telephone to discuss the project and to determine participants’ 
willingness to participate in the study. Participants were asked to fill out questionnaires 
that were delivered through the mail to obtain data on PD and QoL since the original 
study was concluded.  
 
Questionnaires  
 Questionnaires for this follow-up study were essentially the same as the 
questionnaires sent in the original study (McRae et al., 2004) and were sent through the 
mail to participants. The questionnaires included instruments that assessed QoL while 
living with PD. Of the 30 participants from the original study, updated contact 
information was identified for 14 people. These 14 participants were asked to complete 
the questionnaire, and return it in the postage-paid envelope. Of the 14 questionnaires 
sent out, only 11 were returned. Follow-up phone calls were made to the remaining 
participants to determine if there were any problems, and to encourage them to return the 
questionnaires.  
Data gathered from the received questionnaires were then compared to baseline, 
one-year, and two-year information that was previously collected from the participants. 
Trajectories regarding change over time were also determined.   
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Measures 
 
 The following measures can be found in Appendices A through L. These 
measures were sent to participants in the mail to be filled out and returned to the 
investigator. QoL measures were divided into three categories: Physical functioning, 
Emotional functioning, and Social functioning.  
 
Physical Functioning 
Participants’ level of Physical functioning related to PD was assessed by using the 
patient version of the Unified Parkinson’s Disease Rating Scale (UPDRS). The scale was 
developed by Montgomery et al. in 1994 and is an adaptation of the original scale (Fahn 
& Elton, 1987), which is used mainly by medical personnel to assess physical abilities 
and problems. Montgomery et al. (1994) established reliability estimates of the patient 
version of the UPDRS through its use in a health promotion program. The authors found 
that reliability for each of the scales ranged from .65 to .90. The UPDRS has been found 
to have satisfactory construct validity assessed across other instruments measuring PD 
(Ramaker, Marinus, Stiggelbout, & Johannes van Hilten, 2002). The UPDRS was utilized 
to measure the patients’ perspective of Physical functioning abilities and problems related 
to PD. Four scales were used: Activities of Daily Living (ADLs) at “Best” and “Worst” 
and Severity of Symptoms at “Best” and “Worst.” The scales ADLs at Best (when 
patients are physically “at their best”) and ADLs at Worst (when patients are physically 
“at their worst”), each include eight items with ranging scores from (1) Normal, (2) 
Adequate, (3) Limited, (4) Need Help, to (5) Unable to Do. Each scale was separately 
scored, with scores ranging from 8 to 40 points, with lower scores indicating better 
41 
functioning. A sample item from the ADL Scale is, “How well can you turn in bed at 
your best?” Participants were asked to rate their ability to turn in bed ranging from (1) 
Normal, (2) Adequate, (3) Limited, (4) Need Help, and (5) Unable to Do. 
The Severity of Symptoms Scale includes five problems, which participants score 
at “Best” and “Worst” functioning. Each item is rated on the following scale: (1) Normal, 
(2) Mild, (3) Moderate, (4) Severe, and (5) Very Severe. The range of scores is from 5 to 
25, with lower scores indicating better functioning. A sample item from the Severity of 
Symptoms Scale is, “Please rate the severity of tremor at your worst.” Participants were 
asked to rate the severity of tremor on a scale ranging from 1 (Normal) to 5 (Very 
Severe).  
The Free or Restricted Scale was also used to assess Physical functioning of QoL. 
This single, global item measured how free or restricted the person felt “in doing what 
you want to do.” A Likert scale ranging from 1 (I still do everything I want to do) to 7 (I 
can no longer do the things I want to do) was used. Lower scores indicate better 
outcomes.  
 
Emotional Functioning 
The Parkinson’s Disease (PD) Stress Scale was developed to administer to 
German patients with PD (Ellgring, Macht, & Schwartz, 1993, unpublished data). This 
scale has 19 items, with lower scores indicating less stress. Patients were asked to 
indicate either “yes” or “no” as to whether each item described caused them considerable 
stress, or clearly bothered them. Sample items include, “sometimes I am embarrassed in 
public because of my symptoms,” and “I am anxious about the uncertainty of the future 
42 
of my disease.” The estimate of reliability (Cronbach’s alpha) for the scale was .77 
(McRae et al., 2004). The Parkinson’s Disease Stress Scale was based on Ellgring’s 
unpublished work. At the time of its initial inclusion in the study, the scale had not yet 
been validated. It was used in this study without other supporting information, such as a 
measure of validity.  
 The Center for Epidemiologic Studies Depression Scale (CESD; Radloff, 1977) 
was used to assess depressive affect related to QoL. The scale is comprised of 20 items 
and is a self-report assessment of the number and frequency of symptoms of depression. 
Each item is rated on a 4-point scale ranging from 0 to 3 related to frequency of 
experiencing depressive symptoms. Lower scores indicate less depression. For example, 
0 indicates “less than 1 day” and 3 indicates “5 to 7 days.” Sample items include, “I was 
bothered by things that usually don’t bother me” and “I had trouble keeping my mind on 
what I was doing.” Possible total scores could range from 0 to 60.  
 Based on the original study, internal consistency for the CESD was found to be 
.89 (Radloff, 1977). Test-retest reliability was found to be acceptable. Radloff also 
reported the CESD as having excellent concurrent validity by clinical and self-report 
criteria, and substantial evidence of construct validity. The measure was found to be 
highly related to other depression measures that utilize self-report (Radloff, 1977). Craig, 
Richardson, Pass, and Bregman (1985) found a convergent validity measure of 0.65 when 
comparing the CESD with the Hamilton Rating Scale for Depression, an established 
assessment for depression. According to Hughes et al. (1993), CESD scale items have 
been shown to have satisfactory internal consistency, acceptable test-retest stability, good 
concurrent validity, and adequate construct validity.  
43 
 The State-Trait Anxiety Inventory-State (STAI- State; Spielberger, Gorsuch, & 
Lushene, 1970) was developed to assess current, situational aspects of anxiety. State 
anxiety refers to the temporary condition of a person, based on changes in the 
environment, while trait anxiety refers to stable individual differences in anxiety. 
Environmental changes that have little effect on trait anxiety appear to have a more 
significant influence on state anxiety (Metzger, 1976). On this assessment, 20 items are 
rated on a 4-point scale ranging from 1 (not at all) to 4 (very much). Lower scores 
indicated less anxiety. Some examples of questions on this measure include “I feel calm” 
and “I feel jittery.”  
 An early published reliability estimate for the State-Trait Anxiety Inventory-State 
was .89 (Finch Jr., Montgomery, & Deardorff, 1973). Metzger (1976) found the 
assessment to have good discriminating ability for both high and low scoring participants. 
The STAI-State form has been assessed to be a valid measure of anxiety. Okun, Stein, 
Bauman, and Silver (1996) concluded that the STAI-State was a valid measure to assess 
anxiety due to supported content validity. The authors established good content validity 
by comparing the STAI-State to the DSM-IV criteria for Generalized Anxiety Disorder 
(Okun, Stein, Bauman, & Silver, 1996).   
 The Intrusiveness of Illness Scale is a 15-item scale that measured the degree to 
which a chronic illness interferes with usual life activities (Devins et al., 1984). This self-
report questionnaire measures the extent to which the chronic illness, in addition to the 
treatment to the illness, hinders each of 15 life domains that are important to QoL 
(Devins, 1994).  The range of responses for individual items was from 1 (very little) to 7 
(a great deal). Lower scores indicated less intrusiveness. A total score on the 
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Intrusiveness of Illness Scale can range from 15 to 105 (Devins, 1994). Examples of 
items included, “How much does your illness interfere with your ability to work” and 
“How much does your illness interfere with your personal relationships with friends?”  
 The estimate of internal consistency reliability of the Intrusiveness of Illness 
Scale has been consistently high, ranging from .80 to .88 (Devins et al., 1984). When 
examined among participants who do not experience changes in their chronic illness or 
treatment, test-retest reliability has also been high. The Intrusiveness of Illness Scale has 
substantial face validity for participants who have a chronic illness, and can typically be 
completed in 10 minutes (Devins, 1994).  Findings from groups of participants with 
different chronic illnesses support the construct validity of the instrument. For example, 
the level of illness intrusiveness for a sample of patients with multiple sclerosis was 
associated with increased physical disability, neurological impairment, and severity of the 
condition, which was indicated by the standard physical examination (Devins, 1994).   
 
Social Functioning 
The Social Provisions Scale (Cutrona & Russell, 1987) is a 24-item scale that 
measures the perceived degree to which participants’ social relationships provide various 
dimensions of social support. The scale is intended to measure participants’ level of 
perceived social support. The instrument contains 4 items each for categories of social 
relationships, including guidance, reliable alliance, attachment, social integration, 
reassurance of worth, and opportunity to provide nurturance (Cutrona, 1987). A 4-point 
Likert scale ranging from 1 (strongly disagree) to 4 (strongly agree) is used. Lower scores 
indicated less perceived support. Total scores could range from 24 to 96. Examples of 
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items on this measure are “There is someone I could talk to about important decisions in 
my life” and “I have relationships where my competence and skills are recognized.”  
  The estimate of reliability for the Social Provisions Scale was reported to be .91 
(Cutrona, 1989). Cutrona, Russell, and Rose’s (1984) study found internal consistency to 
be above .70 across all provisions when studying 100 elderly subjects. Test-retest 
reliability estimates were found to range from .37 to .66 (Cutrona, Russell, & Rose, 
1984).   
  In a study of first-time mothers, Cutrona (1984) found the Social Provisions Scale 
dimensions of reliable alliance, reassurance of worth, social integration, and guidance 
demonstrated predictive validity of postpartum depression. Women without the six 
provisions of social relationships were more likely to become depressed after their 
pregnancy (Cutrona, 1984). Discriminant validity estimates across the six provisions 
range from .10 to .51 (Cutrona & Russell, 1987). Social integration, reassurance of worth, 
and guidance provisions were found to be significantly related to scores on the UCLA 
Loneliness Scale, demonstrating construct validity (Russell, Peplau, & Cutrona, 1980). 
The Social Contact Scale was developed for the original QoL study by McRae et 
al. (2004). This measure assesses the amount of social interaction or activity experienced 
by the participant. The scale is intended to measure participants’ level of actual social 
support from others. Three items assessing the amount of socializing with friends, 
telephone communication, and participation in public activities were scored on a 6-point 
scale ranging from 1 (not at all) to 6 (all the time). Sample items included, “In the past 
month, how often did you get together socially with friends or relatives” and “During the 
past month, about how often have you done things in public such as shopping, eating in 
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restaurants, going to concerts or movies, etc.?” As a follow-up to each of the three items, 
individuals were asked how satisfied they felt about this level of social contact. Level of 
satisfaction was rated on a Likert scale ranging from 1 (not at all happy) to 7 (extremely 
happy).  
The estimate of reliability for the Social Contact Scale was .69 (McRae et al., 
2004). Measures of social networks, such as social contact and number of relationships, 
were found to correlate with scores on the Social Provisions Scale (Cutrona & Russell, 
1987). Progression of chronic illness appears to be correlated with loss of social contact 
(Ellgring, 1999; Lee et al., 1994; McNamara, Durso, & Harris, 2006). The Social Contact 
measure was developed for the original QoL study (McRae et al., 2004). It was used in 
this study to assess current level of actual social contact, and helped to determine the 
long-term effects of participants’ social QoL. 
 
NEO Five-Factor Inventory  
The NEO Five-Factor Inventory (NEO-FFI) is a 60 item measure of the Five 
Factor Model of personality, which includes Neuroticism, Extraversion, Openness to 
Experience, Agreeableness, and Conscientiousness (Costa & McCrae, 1992). Items 
(descriptions of behavior) are answered on a five point Likert scale, ranging from 
“strongly disagree” to “strongly agree.” Sample items from the inventory include, “I 
often feel tense and jittery” and “I am seldom sad or depressed.” The NEO Five-Factor 
Inventory was administered as a separate assessment from the questionnaire.  
 McRae et al. (2003) investigated the effects of fetal transplantation surgery on 
personality for participants in the double-blind placebo-controlled trial described earlier. 
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The NEO-FFI was administered to participants at baseline, 12, and 24 months after 
receiving the surgery. Results indicated that for all participants, there were no changes on 
any of the five factor scales from baseline to one-year after the surgery. There was a 
significant change among the transplant group that included a decrease in 
Conscientiousness from baseline to 24 months. There were no changes for those who 
were in the placebo group who then received the transplant. The authors concluded that 
personality generally remained stable over the two-year period. 
It has been reported that retest reliability for the five factors range from .86 to .90, 
and internal consistency ranges from .68 to .90 (Costa & McCrae, 1992). The NEO-FFI 
has demonstrated validity and utility in a number of different contexts. It is one of the 
most frequently used measures of the Five-Factor model, and has been translated into 
several languages (McCrae & Costa, 2004).  
 
Data Analyses 
 
Data analyses included two stages, preliminary and primary analysis. During the 
preliminary analysis, demographic information and descriptive statistics were analyzed. 
Composite variables were also created.   
For the primary analyses, data were analyzed using repeated measures analysis of 
variance (ANOVA). Data collected in the present study were compared to data collected 
at baseline, and one and two years following transplantation in the QoL study (McRae et 
al., 2004).  
The repeated measures design is a frequently used ANOVA design in which all 
subjects participate under all levels of the independent variable. It is also referred to as a 
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totally within subjects design. The design method is commonly used in longitudinal 
research. A repeated measures design is used when participants have all received the 
same intervention, or have some important characteristic in common. In this study, the 
individuals participated in the fetal tissue transplantation study (Freed et al., 2001) for the 
purpose of testing an experimental procedure to treat PD. In the repeated measures 
ANOVA, all participants were measured under all conditions. The primary variable used 
included the three dimensions of QoL: Physical functioning, Emotional functioning, and 
Social functioning.  
A repeated measures ANOVA was used to determine changes in participants’ 
responses on the three dimensions. The first research question was: What is the trajectory 
of change in QoL over time for the baseline, one-year, two-year, and current long-term 
follow-up assessments? Analyses were performed separately on the three original 
domains of QoL: Physical functioning, Emotional functioning, and Social functioning. 
The second research question was: Was there any change in personality based on results 
of the NEO-FFI from baseline to the one-year, two-year, and current long-term follow-up 
assessments? Again, the repeated measures analyses were used to investigate any long-
term changes among the five variables of the NEO-FFI: Neuroticism, Extraversion, 
Openness to Experience, Agreeableness, and Conscientiousness.  
 
Summary 
Chapter Three described the methodology used in the present study. Descriptions 
of the participants, procedure, QoL measures, and data analyses were provided. Chapter 
Four presents the preliminary and primary results of the study. 
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Chapter Four
Results of the Study 
Overview 
This chapter presents the results of the statistical analyses associated with the 
current study. The results of the preliminary analyses are discussed, which are then 
followed by the results of the primary analyses utilized to address the research questions. 
All preliminary and primary statistical analyses were performed using the Statistical 
Package for the Social Sciences version 15.0 (SPSS 15.0). All statistical analyses used 
two-tailed tests of significance with an alpha level set at p < .10 due to the small sample 
size.  
Participants originally represented two treatment groups. Those in the original 
transplant group (n = 3) received the fetal tissue transplantation surgery initially during 
the parent study (Freed et al., 2001). Those in the optional transplant group (n = 8) 
received a sham surgery, and later the fetal tissue transplantation procedure during the 
parent study (Freed et al., 2001). In the present study, statistical analyses compared the 
QoL of participants at the baseline, one-year, two-year, and current assessments. Because 
the two treatment groups had surgery at least one year apart, some adjustments were 
needed to equate the time periods for follow-up assessments. In other words, baseline 
data for those in the transplant group were collected approximately two to three months 
before transplantation. However, because of the one-year period of the double-blind 
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condition, for those who initially received the sham surgery, baseline data would have 
been collected approximately 18 months before transplantation. In order to equate the 
time periods involved in the analyses, the 12 month assessment was substituted as the 
baseline assessment for the initial sham group. By using this method of “shifting the 
data” to represent time since surgery instead of calendar time, the data from the two 
original groups were able to be combined and analyzed in terms of baseline, one and two 
years after surgery, and the current assessment. The following preliminary and primary 
analyses were based on the “shifted” variables that were created by combining both 
groups into one group. 
 
Preliminary Analyses 
 This section of the chapter is organized in the following manner: a) participant 
response to questionnaires; b) missing data; c) participants’ demographic information; d) 
descriptive statistics related to the variables analyzed in the research hypotheses; e) 
reliability of variables analyzed in the research hypotheses; f) correlations of Physical and 
Emotional functioning variables, including the assumptions of normality, linearity, and 
homoscedasticity, and the treatment of outliers; and g) discussion on the creation of 
composite variables. 
 
Participant Response of Questionnaires 
Participants from the original QoL study were contacted to determine if they 
would be interested in being involved in the current study. Of the 30 participants in the 
original study, updated contact information was available for 14 people. Questionnaires 
were returned by 11 participants.  
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Data were collected from a total of 11 questionnaires that measured QoL. The 
questionnaires included the three dimensions of QoL: Physical functioning, Emotional 
functioning, and Social functioning. The Physical functioning dimension of QoL was 
assessed by using the patient version of the Unified Parkinson’s Disease Rating Scale 
(UPDRS), including the Activity of Daily Living, Severity of Symptoms, and the Free or 
Restricted scales. The Emotional functioning dimension of QoL was assessed by using 
the Center for Epidemiological Studies- Depression Scale (CESD), the Intrusiveness of 
Illness Scale, the State-Trait Anxiety Inventory-State Scale (STAI), and the Parkinson’s 
Disease Stress Scale. The Social functioning dimension of QoL was assessed by using the 
Social Provisions Scale and the Social Contact Scale. These 11 questionnaires were then 
compared to data collected previously at different time periods, including baseline (prior 
to surgery), one-year after surgery, and two-years after surgery. There was very little 
missing data in the questionnaires.  
 
Missing Data 
 
There was very little missing data in this study, primarily because of participant 
commitment to the project, and perhaps because participants were paid $25 for each 
completed questionnaire. Participants were not paid for the most recent set of returned 
questionnaires.  
 
Demographic Information 
 
A demographic questionnaire (Appendix J) was used to collect information on the 
participants’ demographic characteristics, which are presented in Table 1. As previously 
stated in Chapter Three, this study was based on participants with PD who received fetal 
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tissue transplantation surgery 10-12 years ago. Participants represented two treatment 
groups, based on the time they received the fetal tissue transplantation surgery. Those in 
the original transplant group (n = 3) received the fetal tissue transplantation procedure 
initially during the parent study (Freed et al., 2001). Those in the optional transplant 
group (n = 8) received a sham surgery, and later the fetal tissue transplantation procedure 
during the parent study (Freed et al., 2001). For the purpose of the present study, the 
demographic data is presented for the total sample of 11 individuals who participated in 
the current iteration of data collection.  
An interesting find when looking at the demographic information of the 
participants (Table 1) is that a majority of them are currently employed or volunteering, 
despite the progressive nature of PD. Participants 6, 10, and 11 currently are employed, 
while Participants 1, 2, 3, 7, 8, and 9 are currently volunteering.  
 
Descriptive Statistics 
Descriptive analyses of the QoL measures included in the study were performed 
to determine if the responses were normally distributed and if the data showed sufficient 
variability (see Table 2). The descriptive analyses included the number of respondents, 
means, and standard deviations. Each QoL dimension included four time periods 
representing baseline (prior to surgery), one year after surgery, two years after surgery, 
and the current assessment.  
Descriptive analyses of the NEO Five-Factor Inventory (NEO-FFI) scales 
(Neuroticism, Extraversion, Openness to Experience, Agreeableness, and 
Conscientiousness) were included to determine if the responses were normally distributed 
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and if the data showed sufficient variability (see Table 3). The descriptive analyses 
included the number of respondents, means, and standard deviations. All five components 
of the NEO-FFI included four time periods representing baseline (prior to surgery), one 
year after surgery, two years after surgery, and the current assessment.  
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Table 2 
Descriptive Statistics of QoL Variables for Baseline, One-Year, Two-Year, and Current 
Assessment 
QoL Variable (includes time of assessment) N Mean S.D. 
Physical Functioning     
     Activities of Daily Living at Worst Scale    
          Baseline 11 27.36 6.67 
          One-Year 11 23.82 7.78 
          Two-Year 9 20.67 7.21 
          Current 11 26.27 6.94 
     Severity of Symptoms at Worst Scale    
          Baseline 11 12.09 2.67 
          One-Year 11 12.18 3.40 
          Two-Year 9 10.89 3.79 
          Current 11 13.72 3.38 
     Free or Restricted Scale    
          Baseline 11 3.91 1.64 
          One-Year 11 3.55 1.57 
          Two-Year 9 3.00 1.50 
          Current 11 4.05 1.74 
Emotional Functioning     
     Center for Epidemiological Studies - Depression Scale    
          Baseline 11 30.91 9.24 
          One-Year 11 27.91 5.91 
          Two-Year 9 30.22 6.55 
          Current 10 32.90 7.81 
     Intrusiveness of Illness Scale    
          Baseline 11 61.64 19.02 
          One-Year 11 58.64 19.96 
          Two-Year 9 58.11 19.76 
          Current 10 59.10 22.54 
     State-Trait Anxiety Inventory - State Scale    
          Baseline 11 30.73 9.54 
          One-Year 11 34.27 9.55 
          Two-Year 9 33.89 8.22 
          Current 11 39.36 6.98 
     Parkinson’s Disease Stress Scale    
          Baseline 11 6.18 3.49 
          One-Year 11 6.91 3.18 
          Two-Year 9 5.44 4.61 
          Current 11 8.59 3.09 
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Table 2, continued 
Descriptive Statistics of QoL Variables for Baseline, One-Year, Two-Year, and Current 
Assessment 
QoL Variable (includes time of assessment) N Mean S.D. 
Social Functioning     
     Social Provisions Scale    
          Baseline 11 85.18 9.00 
          One-Year 11 82.55 8.32 
          Two-Year 9 83.33 7.94 
          Current 11 73.18 11.43 
     Social Contact Scale    
          Baseline 11 14.27 3.44 
          One-Year 11 13.82 3.54 
          Two-Year 9 13.22 3.77 
          Current 11 12.36 4.13 
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Table 3 
Descriptive Statistics of NEO-FFI Variables for Baseline, One-Year, Two-Year, and 
Current Assessment 
NEO-FFI Variable (includes time of assessment) N Mean S.D. 
Neuroticism - Baseline 11 13.09 7.71 
Neuroticism - One-Year 11 14.09 7.12 
Neuroticism - Two-Year 9 13.56 6.54 
Neuroticism - Current 10 18.70 3.27 
    
Extraversion - Baseline 11 31.27 6.53 
Extraversion - One-Year 11 30.00 7.63 
Extraversion - Two-Year 9 28.56 6.82 
Extraversion - Current 9 27.78 3.56 
    
Openness to Experience - Baseline 11 34.27 5.66 
Openness to Experience - One-Year 11 33.18 4.21 
Openness to Experience - Two-Year 9 34.67 4.00 
Openness to Experience - Current 10 31.30 4.55 
    
Agreeableness - Baseline 11 35.27 4.00 
Agreeableness - One-Year 11 34.45 3.70 
Agreeableness - Two-Year 9 35.33 5.10 
Agreeableness - Current 10 32.70 3.74 
    
Conscientiousness - Baseline 11 34.00 5.73 
Conscientiousness - One-Year 11 31.27 6.36 
Conscientiousness - Two-Year 9 31.22 6.08 
Conscientiousness - Current 9 28.22 4.02 
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Reliability of Measures 
Estimates of reliability (Cronbach’s alpha) of QoL measures for the current 
assessment were conducted as part of the preliminary analyses (see Table 4). Because the 
Free or Restricted variable of the UPDRS is a single item, no reliability coefficient was 
calculated. Although two scales had somewhat low reliability values (Severity of 
Symptoms at Worst Scale and Parkinson’s Disease Stress Scale), it was decided to 
include these scales in the analyses because they were used in previous work with these 
data.  
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Table 4 
Reliability of QoL Measures for Current Assessment 
QoL Measure at Current Assessment Cronbach’s Alpha 
  
Physical Functioning  
Activities of Daily Living at Worst Scale 
Severity of Symptoms at Worst Scale 
.88 
.68 
Emotional Functioning  
Center for Epidemiological Studies - Depression Scale  
Intrusiveness of Illness Scale 
State-Trait Anxiety Inventory - State Scale  
Parkinson’s Disease Stress Scale 
.84 
.94 
.86 
.67 
Social Functioning  
Social Provisions Scale 
Social Contact Scale 
.95 
.84 
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Correlations of Quality of Life Variables 
 
Correlations of the measures comprising the Physical and Emotional dimensions 
of QoL were calculated to describe the strength and direction of the linear relationship 
between the variables. The Social Provisions Scale and Social Contact Scale were not 
strongly correlated from the beginning of data collection so the Social functioning 
measures continued to be analyzed separately in this study.  
First, the Physical functioning dimension of QoL was analyzed. Preliminary 
analyses were performed to indicate that there was no violation of the assumptions of 
normality, linearity, and homoscedasticity for the variables for Activities of Daily Living 
at Worst Scale, Severity of Symptoms at Worst Scale, and Free or Restricted Scale. An 
examination of the data indicated that the responses were normally distributed and that 
there was sufficient variability within the sample. Scores on each variable appeared to be 
relatively normally distributed after viewing the histograms. After inspecting the boxplot 
for each variable, participant 8 was considered to be an outlier for the Activities of Daily 
Living at Worst Scale. In addition to being a very small sample size, because the values 
of the 5% trimmed mean and mean for the Activities of Daily Living at Worst Scale 
appear to be close, this data remained in the data set. Shapiro-Wilks statistics for test of 
normality revealed no violations of the assumption of normality for the three variables of 
Physical functioning. In addition, the normal probability plots indicated a normal 
distribution. Scatterplots for all three variables indicated there was not a violation for the 
linearity and homoscedasticity assumptions. By there being no violations to the 
assumptions of normality, linearity, and homoscedasticity, the data were considered to be 
independent of one another. 
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The relationships between the Activities of Daily Living at Worst Scale, Severity 
of Symptoms at Worst Scale, and Free or Restricted Scale were investigated using a 
Pearson correlation coefficient. Correlation coefficients are presented in Table 5. Results 
indicated strong, positive correlations among the measures, which justified putting them 
together to create the composite variable of Physical functioning.  
Next, the Emotional functioning dimension of QoL was analyzed. Preliminary 
analyses were performed to determine whether there were any violations of the 
assumptions of normality, linearity, and homoscedasticity for the measures of Center for 
Epidemiological Studies - Depression Scale (CESD), the Intrusiveness of Illness Scale, 
the State-Trait Anxiety Inventory - State Scale (STAI), and the Parkinson’s Disease 
Stress Scale. Scores on each variable appeared to be relatively normally distributed after 
viewing the histograms. After inspecting the boxplot for each variable, participant 3 was 
considered to be an outlier for the CESD. In addition to being a very small sample size, 
because the values of the 5% trimmed mean and mean for the CESD appeared to be 
close, these data remained in the data set. The boxplot also indicated that participant 11 
was considered to be an outlier for the Parkinson’s Disease Stress Scale. In addition to 
being a very small sample size, because the values of the 5% trimmed mean and mean for 
the CESD appear to be close, this case remained in the data set. Shapiro-Wilks statistics 
for test of normality revealed no violations of the assumption of normality for the four 
measures comprising Emotional functioning. In addition, the normal probability plots 
indicated a normal distribution. Scatterplots for all three variables indicated there was not 
a violation for the linearity and homoscedasticity assumptions.  By there being no 
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violations to the assumptions of normality, linearity, and homoscedasticity, the data were 
considered to be independent of one another. 
The relationships between the Center for Epidemiological Studies- Depression 
Scale, the Intrusiveness of Illness Scale, the State-Trait Anxiety Inventory - State Scale, 
and the Parkinson’s Disease Stress Scale were investigated using a Pearson correlation 
coefficient. Correlation coefficients are presented in Table 6. Results indicated that two 
of the correlations were not strong (.14 and .03). However, because these four measures 
had been combined to create the composite variable Emotional functioning in previous 
work with these data, it was decided to proceed to the next step of preliminary analyses, 
which was determining the reliability of the composite variables.  
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Table 5 
 
Correlation Coefficients for Physical Functioning Variables (scales of Unified  
 
Parkinson’s Disease Rating Scale) 
 
QoL Physical Functioning Variable Activities 
of Daily 
Living at 
Worst 
Severity of 
Symptoms 
at Worst  
 
Free or 
Restricted  
 
Activities of Daily Living at Worst Scale 
Pearson Correlation 
Significance 
N 
 
1 
 
11 
  
Severity of Symptoms at Worst Scale 
Pearson Correlation 
Significance 
N 
 
.76** 
.01 
11 
 
1 
 
11 
 
Free or Restricted Scale 
Pearson Correlation 
Significance 
N 
 
.61* 
.05 
11 
 
.75** 
.01 
11 
 
1 
 
11 
 
*p < .05 level, two tailed. **p < .01 level, two tailed. 
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Table 6 
 
Correlation Coefficients for Emotional Functioning Variables 
 
QoL Emotional Functioning 
Variable 
Center for 
Epidemiological 
Studies 
Intrusiveness 
of Illness 
Scale  
State-
Trait 
Anxiety 
Inventory  
Parkinson’s 
Disease 
Stress 
Scale 
 
Center for Epidemiological 
Studies - Depression Scale 
Pearson Correlation 
Significance 
N 
 
 
1 
 
10 
   
Intrusiveness of Illness Scale 
Pearson Correlation 
Significance 
N 
 
.38 
.28 
10 
 
1 
 
11 
  
State-Trait Anxiety 
Inventory - State  
Pearson Correlation 
Significance 
N 
 
 
.56 
.09 
10 
 
 
.14 
.70 
10 
 
 
1 
 
11 
 
Parkinson’s Disease Stress 
Scale 
Pearson Correlation 
Significance 
N 
 
 
.71* 
.02 
10 
 
 
.60 
.07 
10 
 
 
.03 
.92 
11 
 
 
1 
 
11 
 
*p < .05 level, two tailed.  
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Composite Variables 
 
Composite variables were created for Physical functioning and Emotional 
functioning to reduce the number of variables and improve the strength of the statistical 
analyses. Based on previous research with these variables and the correlation among each 
set of variables, standardized scores (or z-scores) were created for each of the measures 
so they could then be combined to create a total z-score representing the composite 
variable. Scores for each measure were standardized at each period based on the mean 
and standard deviation of the measure at baseline. Estimates of reliability (Cronbach’s 
alpha) were then calculated for the composite variable of Physical functioning and 
Emotional functioning. Reliability estimates were .88 and .74 respectively (see Table 7). 
 Social functioning was assessed by the two individual scales, Social Provisions 
Scale and Social Contact Scale due to low correlations between the measures. For the 
following primary analyses, the two composite variables and two social support measures 
were used.  
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Table 7 
Reliability of QoL Measures for Current Assessment - Composite Variables 
QoL Measure at Current Assessment Cronbach’s Alpha 
  
Physical Functioning - Composite Variable 
 
UPDRS scales:  
 
Activities of Daily Living at Worst  
Severity of Symptoms at Worst  
Free or Restricted  
.88 
  
Emotional Functioning - Composite Variable 
 
Center for Epidemiological Studies - Depression Scale  
Intrusiveness of Illness Scale 
State-Trait Anxiety Inventory - State  
Parkinson’s Disease Stress Scale 
.74 
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Primary Analyses 
The preceding section addressed demographic information and other preliminary 
analyses. The following section focuses on the analyses and results for the research 
questions of the study. The alpha level was set at p < .10 for all statistical analyses due to 
the small sample size. By using the .10 alpha level, there is an increased chance that a 
Type I error might have occurred, and a decreased chance that a Type II error might have 
occurred.  
 
Research Question #1 
 
What is the trajectory of change in QoL over time for the baseline, one-year, two-year, 
and current long-term follow-up assessment? Analyses were performed separately on the 
three original domains of QoL: Physical functioning, Emotional functioning, and Social 
functioning. 
 A one-way repeated measures analysis of variance (ANOVA) was conducted to 
assess longitudinal changes over time. Scores were first compared on the QoL dimension 
of Physical functioning at the following times that assessments were administered: 
baseline (prior to receiving fetal tissue transplantation), one year after the surgery, two 
years after the surgery, and the current assessment (10-12 years after the surgery). The 
Physical functioning dimension of QoL included the following measures: Unified 
Parkinson’s Disease Rating Scale (UPDRS) scales of Activities of Daily Living at Worst 
and Severity of Symptoms at Worst, and the Free or Restricted variable. 
 Results of this analysis revealed a significant quadratic change in Physical 
functioning over time when comparing the baseline, one-year, two-year, and current 
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assessments, F (3,6) = 9.14, p < .05. The .53 multivariate partial eta squared indicated a 
large effect size (Keppell & Wickens, 2004). A profile plot is presented in Figure 1, 
which shows the mean values of Physical functioning for the baseline, one-year, two-
year, and current assessments. It appears that marked improvement in Physical 
functioning occurred between baseline and two years following surgery with a decline in 
self-reported functioning occurring from two years to the current assessment.  
Figure 2 demonstrates the line of progression of Physical functioning for each 
participant for the baseline, one-year, two-year, and current assessments. Physical 
functioning scores appear to have some minor fluctuation between the baseline and two-
year assessments, while there was a considerable decline in scores between the two-year 
and current assessments.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 
Trajectory of Change of Physical Functioning for Baseline, One-Year, Two-Year, and 
Current Assessments (lower scores mean improved functioning) 
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Figure 2 
Line of Progression of Physical Functioning for Each Participant for Baseline, One-Year,  
Two-Year, and Current Assessments (lower scores mean improved functioning) 
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A one-way repeated measures analysis of variance (ANOVA) was conducted to 
assess longitudinal changes on the QoL dimension of Emotional functioning at the 
following times that assessments were administered: baseline (prior to receiving fetal 
tissue transplantation), one year after the surgery, two years after the surgery, and the 
current assessment (10-12 years after the surgery). The Emotional functioning dimension 
of QoL included the following measures: Center for Epidemiological Studies - 
Depression Scale (CESD), the Intrusiveness of Illness Scale, the State-Trait Anxiety 
Inventory - State scale (STAI), and the Parkinson’s Disease Stress Scale.  
Results of this analysis revealed a significant quadratic change in Emotional 
functioning over time when comparing the baseline, one-year, two-year, and current 
assessments, F (3,5) = 5.15, p < .10. The .42 multivariate partial eta squared indicated a 
large effect size (Keppell & Wickens, 2004). A profile plot is presented (see Figure 3) to 
show the mean values of Emotional functioning for the baseline, one-year, two-year, and 
current assessments. In a profile very similar to Physical functioning, there appears to be 
an improvement in Emotional functioning that occurred between baseline and two years 
following surgery with a decline in Emotional functioning occurring from two years to 
the current assessment.  
Figure 4 demonstrates the line of progression of Emotional functioning for each 
participant for the baseline, one-year, two-year, and current assessments.  Emotional 
functioning scores appear to have some minor fluctuation between the baseline and two-
year assessments, while there was a more significant decline in scores between the two-
year and current assessments.   
 
Figure 3 
Trajectory of Change of Emotional Functioning for Baseline, One-Year, Two-Year, and 
Current Assessments (lower scores mean improved functioning) 
-0.3
-0.2
-0.1
0
0.1
0.2
0.3
0.4
Baseline One-Year Two-Year Current
Time of Assessment
Em
ot
io
na
l F
un
ct
io
ni
ng
 M
ea
n 
(z
-s
co
re
)
 
 
 
 
 
 
71 
Figure 4 
Line of Progression of Emotional Functioning for Each Participant for Baseline,  
One-Year, Two-Year, and Current Assessments (lower scores mean improved 
functioning) 
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A one-way repeated measures analysis of variance (ANOVA) was conducted to 
assess longitudinal changes on the QoL dimension of Social functioning at the following 
times that assessments were administered: baseline (prior to receiving fetal tissue 
transplantation), one year after the surgery, two years after the surgery, and the current 
assessment (10-12 years after the surgery). The Social functioning dimension of QoL that 
was examined in this analysis was the Social Provisions Scale.  
There was a significant cubic effect for time, F (3,6) = 7.85, p < .05 for the Social 
Provisions Scale. The .50 multivariate partial eta squared indicated a large effect size 
(Keppell & Wickens, 2004). Between the two-year assessment and the current 
assessment, perceived social support dropped well below previous levels. A profile plot is 
provided (see Figure 5) to indicate the mean values of Social functioning from the Social 
Provisions Scale for the baseline, one-year, two-year, and current assessments.  
Figure 6 demonstrates the line of progression of Social functioning from the 
Social Provisions Scale for each participant for the baseline, one-year, two-year, and 
current assessments. Based on the figure, scores dropped between the baseline and two-
year assessments. Scores greatly decreased between the two-year and current 
assessments.  
 
 
 
 
 
 
Figure 5 
Trajectory of Change of Social Provisions Scale for Baseline, One-Year, Two-Year, and 
Current Assessments (higher scores mean improved functioning) 
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Figure 6 
Line of Progression of Social Functioning from the Social Provisions Scale for Each 
Participant for Baseline, One-Year, Two-Year, and Current Assessments (higher scores 
mean improved functioning) 
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A one-way repeated measures analysis of variance (ANOVA) was conducted to 
assess longitudinal changes on the QoL dimension of Social functioning at the following 
times that assessments were administered: baseline (prior to receiving fetal tissue 
transplantation), one year after the surgery, two years after the surgery, and the current 
assessment (10-12 years after the surgery). The Social functioning dimension of QoL that 
was examined in this analysis was the Social Contact Scale.  
Results of this analysis revealed there were no significant changes in Social 
functioning over time when comparing the Social Contact Scale from the baseline, one-
year, two-year, and current assessments. A profile plot is presented (see Figure 7) to 
show the mean values of Social functioning from the Social Contact Scale for the 
baseline, one-year, two-year, and current assessments.  
Figure 8 demonstrates the line of progression of Social functioning from the 
Social Contact Scale for each participant for the baseline, one-year, two-year, and current 
assessments. Participants’ scores remained relatively consistent between the baseline and 
two-year assessments, while there was a steady drop in scores between the two-year and 
current assessments.  
 
 
 
 
 
 
 
Figure 7 
Trajectory of Change of Social Contact Scale for Baseline, One-Year, Two-Year, and 
Current Assessments (higher scores mean improved functioning) 
11.5
12
12.5
13
13.5
14
Baseline One-Year Two-Year Current
Time of Assessment
So
ci
al
 C
on
ta
ct
 S
ca
le
 M
ea
n
 
 
77 
Figure 8 
Line of Progression of Social Functioning from the Social Contact Scale for Each 
Participant for Baseline, One-Year, Two-Year, and Current Assessments (higher scores 
mean improved functioning) 
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Research Question #2 
Was there any change in personality based on results of the NEO-FFI for the baseline, 
one-year, two-year, and current long-term follow-up assessment? Analyses were 
performed separately on the five variables of the NEO-FFI: Neuroticism, Extraversion, 
Openness to Experience, Agreeableness, and Conscientiousness.  
A one-way repeated measures analysis of variance (ANOVA) was conducted to 
assess longitudinal changes over time. Scores were first compared on the NEO-FFI 
variable of Neuroticism at the following times that assessments were administered: 
baseline (prior to receiving fetal tissue transplantation), one year after the surgery, two 
years after the surgery, and the current assessment (10-12 years after the surgery).  
Results of this analysis revealed there was a significant cubic change in 
Neuroticism over time when comparing the baseline, one-year, two-year, and current 
assessments, F (3,5) = 4.55, p < .10. The .39 multivariate partial eta squared indicated a 
large effect size (Keppell & Wickens, 2004). A profile plot shown in Figure 9 presents 
the mean values of Neuroticism for the baseline, one-year, two-year, and current 
assessments. This figure indicates that Neuroticism increased a great deal between the 
two-year and current assessments.  
Figure 10 demonstrates the line of progression of Neuroticism for each participant 
for the baseline, one-year, two-year, and current assessments. This figure indicates that 
while there was a decline in scores between the one-year and two-year assessments, 
scores across participants increased between the two-year and current assessments.   
 
 
Figure 9 
Trajectory of Change of NEO-FFI: Neuroticism for Baseline, One-Year, Two-Year, and 
Current Assessments (higher scores mean improved functioning) 
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Figure 10 
Line of Progression of Neuroticism from the NEO-FFI for Each Participant for Baseline, 
One-Year, Two-Year, and Current Assessments (higher scores mean improved 
functioning) 
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A one-way repeated measures analysis of variance (ANOVA) was conducted to 
assess longitudinal changes of the NEO-FFI variable of Extraversion at the following 
times that assessments were administered: baseline (prior to receiving fetal tissue 
transplantation), one year after the surgery, two years after the surgery, and the current 
assessment (10-12 years after the surgery).  
 There was a significant effect for time (cubic pattern of change) for the 
Extraversion variable of the NEO-FFI, F (3,5 ) = 6.95, p < .05. The .50 multivariate 
partial eta squared indicated a large effect size (Keppell & Wickens, 2004). A profile plot 
is presented (see Figure 11) which indicates the mean values of Extraversion for the 
baseline, one-year, two-year, and current assessments. Scores decreased after baseline, 
and improved between the one-year and two-year assessments. Scores decreased between 
the two-year and current assessments.  
Figure 12 demonstrates the line of progression of Extraversion for each 
participant for the baseline, one-year, two-year, and current assessments. This figure also 
indicates a fluctuation between scores over the four time periods.  
 
 
 
 
 
 
 
 
Figure 11 
Trajectory of Change of NEO- FFI: Extraversion for Baseline, One-Year, Two-Year, and 
Current Assessments (higher scores mean improved functioning) 
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Figure 12 
Line of Progression of Extraversion from the NEO-FFI for Each Participant for Baseline, 
One-Year, Two-Year, and Current Assessments (higher scores mean improved 
functioning) 
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A one-way repeated measures analysis of variance (ANOVA) was conducted to 
assess longitudinal changes of the NEO-FFI variable of Openness to Experience at the 
following times that assessments were administered: baseline (prior to receiving fetal 
tissue transplantation), one year after the surgery, two years after the surgery, and the 
current assessment (10-12 years after the surgery).  
 There was a significant effect for time (cubic pattern of change) for the Openness 
to Experience variable of the NEO-FFI, F (3,5 ) = 8.66, p < .05. The .55 multivariate 
partial eta squared indicated a large effect size (Keppell & Wickens, 2004). The greatest 
amount of change occurred between the two-year and current assessments. A profile plot 
is presented (see Figure 13) to indicate the mean values of Openness to Experience for 
the baseline, one-year, two-year, and current assessments. According to Figure 13, scores 
decreased after baseline, but improved between the one-year and two-year assessments. 
Based on the figure, scores appear to have decreased significantly between the two-year 
and current assessments.  
Figure 14 demonstrates the line of progression of Openness to Experience for 
each participant for the baseline, one-year, two-year, and current assessments. According 
to Figure 14, scores improved between the baseline and two-year assessments, but then 
dropped over time.  
 
 
 
 
 
Figure 13 
Trajectory of Change of NEO-FFI: Openness to Experience for Baseline, One-Year, 
Two-Year, and Current Assessments (higher scores mean improved functioning) 
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Figure 14 
Line of Progression of Openness to Experience from the NEO-FFI for Each Participant 
for Baseline, One-Year, Two-Year, and Current Assessments (higher scores mean 
improved functioning) 
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A one-way repeated measures analysis of variance (ANOVA) was conducted to 
assess longitudinal changes of the NEO-FFI variable of Agreeableness at the following 
times that assessments were administered: baseline (prior to receiving fetal tissue 
transplantation), one year after the surgery, two years after the surgery, and the current 
assessment (10-12 years after the surgery).  
 Results of this analysis revealed there were no significant changes in 
Agreeableness over time when comparing the baseline, one-year, two-year, and current 
assessments. A profile plot is presented (see Figure 15) to show the mean values of 
Agreeableness for the four time periods.  
Figure 16 demonstrates the line of progression of Agreeableness for each 
participant for the baseline, one-year, two-year, and current assessments. Scores appeared 
to fluctuate between the baseline and two-year assessments.  
 
 
 
 
 
 
 
 
 
 
 
Figure 15 
Trajectory of Change of NEO-FFI: Agreeableness for Baseline, One-Year, Two-Year, 
and Current Assessments (higher scores mean improved functioning) 
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Figure 16 
Line of Progression of Agreeableness from the NEO-FFI for Each Participant for 
Baseline, One-Year, Two-Year, and Current Assessments (higher scores mean improved 
functioning) 
 
25
29
33
37
41
45
Baseline One-Year Two-Year Current
Time of Assessment
A
gr
ee
ab
le
ne
ss
 M
ea
n
Participant 1 Participant 2 Participant 3 Participant 4
Participant 5 Participant 6 Participant 7 Participant 8
Participant 9  Participant 10 Participant 11 Normative Score
                  Missing Data  
 
 
90 
91 
A one-way repeated measures analysis of variance (ANOVA) was conducted to 
assess longitudinal changes of the NEO-FFI variable of Conscientiousness at the 
following times that assessments were administered: baseline (prior to receiving fetal 
tissue transplantation), one year after the surgery, two years after the surgery, and the 
current assessment (10-12 years after the surgery).  
There was a significant cubic effect for time for Conscientiousness when 
comparing the baseline, one-year, two-year, and current assessments, F (3,5) = 4.8, p < 
.10. The .41 multivariate partial eta squared indicated a large effect size (Keppell & 
Wickens, 2004). A profile plot is shown (see Figure 17) to present the mean values of 
Conscientiousness for the baseline, one-year, two-year, and current assessments. There 
appears to be a progressively downward trend in the data over time, especially from the 
two-year assessment to the present.  
Figure 18 demonstrates the line of progression of Conscientiousness for each 
participant for the baseline, one-year, two-year, and current assessments. According to 
the figure, scores decreased after the baseline assessment, then improved slightly until the 
two-year assessment. Scores generally declined between the two-year and current 
assessments.  
 
 
 
 
 
 
Figure 17 
Trajectory of Change of NEO-FFI: Conscientiousness for Baseline, One-Year,  
Two-Year, and Current Assessments (higher scores mean improved functioning) 
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Figure 18 
Line of Progression of Conscientiousness from the NEO-FFI for Each Participant for 
Baseline, One-Year, Two-Year, and Current Assessments (higher scores mean improved 
functioning) 
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There were 30 participants in the original Qol study (McRae, 2004). Of that 
number, some participants in the original sham surgery group did not receive the 
transplant, some participants passed away, while others were either not able to be located 
due to outdated contact information or were not interested in participating in the current 
study. Therefore, there were only 11 participants in the present investigation.  
In order to examine differences between the 11 current participants and the other 
19 participants in the original QoL study, scores on QoL, medical, and personality 
variables were compared. Results indicated that participants’ age (p < .01), gender (p < 
.10), level of actual support (p < .05), Extraversion (p < .10), and Openness to Experience 
(p < .05) were found to be significantly different when comparing participants in the 
present study to the remaining participants from the QoL study. Participants were 
younger in the present investigation when compared to the remaining QoL participants. 
There were also more female participants in the current study. Participants in the present 
investigation also reported higher levels of actual support, Extraversion, and Openness to 
Experience.  
There were no significant differences between the means of the participants in the 
present study and the remaining participants from the original QoL study for the Physical 
and Emotional functioning dimensions of QoL, medical variables, or for the personality 
factors of Neuroticism, Agreeableness, and Conscientiousness.  
 
Summary 
Chapter Four presented the results of the statistical analyses associated with the 
current study. The results of the preliminary analyses were discussed, which were 
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then followed by the results of the primary analyses utilized to address the research 
questions.  
 A one-way repeated measures analysis of variance (ANOVA) was conducted to 
assess longitudinal changes over time with an alpha level set at p < .10. Scores were 
compared on the QoL dimensions of Physical functioning, Emotional functioning, and 
Social functioning at the following times that assessments were administered: baseline 
(prior to receiving fetal tissue transplantation), one year after the surgery, two years after 
the surgery, and the current assessment (10-12 years after the surgery). Results of the 
analyses revealed there was a significant effect for time for the Physical functioning, 
Emotional functioning, and Social Provisions Scale variables of QoL.  
 A one-way repeated measures analysis of variance (ANOVA) was conducted to 
assess longitudinal changes over time with an alpha level set at p < .10 on the five 
variables of the NEO-FFI: Neuroticism, Extraversion, Openness to Experience, 
Agreeableness, and Conscientiousness. Results of the analyses revealed there was a 
significant effect for time for the Neuroticism, Extraversion, Openness to Experience, and 
Conscientiousness scales of the NEO-FFI. All effect sizes for significant changes were 
considered to be large. This indicated a very large magnitude of change, suggesting there 
was a strong effect between the fetal tissue transplantation surgery and the QoL variables 
and NEO-FFI factors.   
 Chapter Five will discuss the results presented in Chapter Four, as well as the 
limitations associated with this study and recommendations for future research.  
 
96 
Chapter Five
Discussion 
Overview 
Chapter Five will cover the following topics: a) brief summary of the study, b) 
discussion of the overall findings related to the research questions, c) limitations of the 
study, d) recommendations for future research, and e) conclusions. 
 
Summary of the Study 
Research has led to great improvements in surgical techniques for PD.  Surgical 
procedures for PD may be considered when drug therapy is no longer effective. Different 
surgical procedures have been used over time to reduce symptoms of the disease. Since 
1988, patients with PD have been involved in clinical trials investigating the efficacy of 
neural transplantation of fetal tissue into the brains of those affected with the disorder 
(Clarkson & Freed, 1999). Fetal tissue transplantation surgery has been used as an 
experimental surgical treatment to improve PD symptoms (Bethchen & Kaplitt, 2003; 
Freed, Greene, & Breeze, 2001). 
While there is little research on the effectiveness of fetal tissue transplantation 
surgery as a treatment for PD, there is even less literature on long-term effects of this 
treatment (Hagell et al., 2002; Rosser & Dunnett, 2003). An even more limited amount of 
research exists on how QoL is affected by fetal tissue transplant surgery (McRae et al., 
2004) in those with PD.  
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This study examined the longitudinal effects on QoL for individuals who 
participated in a fetal tissue transplantation surgery trial beginning in 1995. Participants 
were part of a parent study (Freed et al., 2001) that determined the effectiveness of fetal 
tissue transplantation. In the parent study (Freed et al., 2001), 20 participants were 
randomly assigned to receive the fetal tissue transplantation procedure, while the other 20 
participants received a sham surgery with the understanding that they could receive the 
fetal tissue transplantation procedure at a later time. Patients and medical staff were blind 
to the type of surgery participants received until 13 months following the surgery. The 
purpose of the parent study was to assess whether participants who received the fetal 
tissue transplantation procedure improved significantly more than those who received the 
sham surgery, or placebo. 
Participants were asked to complete questionnaires assessing QoL (McRae et al., 
2004). Data were collected before surgery, and at four, eight, and 12 months after surgery 
before the blind was lifted. The purpose of the original QoL study was to determine if 
there were differences in QoL when comparing those who received the fetal tissue 
transplantation procedure to those who received the sham surgery (McRae et al., 2004).  
In the present study, current data collected on QoL were compared with baseline, 
one-year, and two-year data on QoL from the original study (McRae et al., 2004). The 
study specifically addressed the following research questions: 
 
1. What was the trajectory of change in QoL over time for the baseline, one-year, two-
year, and current long-term follow-up assessment? Analyses were performed 
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separately on the three original domains of QoL: Physical functioning, Emotional 
functioning, and Social functioning. 
2. Was there any change in personality based on results of the NEO-FFI for the 
baseline, one-year, two-year, and current long-term follow-up assessment? 
 
Discussion of Overall Findings 
 The first research question was investigated to determine longitudinal changes of 
the three dimensions of QoL for those who received the fetal tissue transplantation 
surgery. Scores were first compared on the QoL dimension of Physical functioning at the 
following times that assessments were administered: baseline (prior to receiving fetal 
tissue transplantation), one year after the surgery, two years after the surgery, and the 
current assessment (10-12 years after the surgery) to assess longitudinal changes over 
time. The Physical functioning dimension of QoL included the following measures: 
Unified Parkinson’s Disease Rating Scale (UPDRS) scales of Activities of Daily Living 
at Worst and Severity of Symptoms at Worst, and the Free or Restricted variable. 
 Results of this analysis revealed a significant quadratic change in Physical 
functioning over time when comparing the baseline, one-year, two-year, and current 
assessments. Patients reported an improved level of Physical functioning from baseline to 
the two years following surgery (lower scores mean better functioning). Most 
improvement was reported between the baseline and one-year assessments (about .4) with 
improvement from one year to two years being half that, or about .2. In the interval 
between the two-year and the current assessments (an average of nine years), most 
patients reported a decline in Physical functioning. Patients reported having reduced 
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Physical functioning after the two-year assessment up to the present time. Impairment in 
Physical functioning might include more difficulty with performing activities of daily 
living, such as walking, writing, and talking. Greater impairment in Physical functioning 
could also include an increase in participants’ severity of symptoms, such as more severe 
tremors, greater difficulty with swallowing, or a higher frequency of falls. Participants 
may also currently feel that they cannot do the things they want to do, when compared to 
assessments at previous time periods. This trend in a decline in Physical functioning 
might be expected due to PD’s chronic, progressive nature (Guttman, Kish, & Furukawa, 
2003; Hagell et al., 2002). It is interesting to note that in Figure 2, one person (Participant 
2) reported improvement in Physical functioning from the two-year to the current 
assessment. Because of the varying amounts of time between the two-year and current 
assessments and because there were no intermediate assessments made after two years, it 
is impossible to determine a more exact trajectory of change over time.  
Results of the current study revealed a significant quadratic change in Emotional 
functioning across time. Participants reported improved Emotional functioning between 
the baseline and two-year time period. Consistent with Physical functioning, there was a 
decrease in Emotional functioning between the two-year and current assessments (lower 
scores mean better functioning). In addition to an improvement in Physical functioning, 
Figure 4 indicates that Participant 2 reported improvement in Emotional functioning from 
the two-year to the current assessment. Participant 4 also improved in Emotional 
functioning from the two-year to the current assessment. As in Physical functioning, it is 
impossible to determine a more exact trajectory of change over time due to the varying 
amounts of time between the two-year and current assessments and because there were 
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no intermediate assessments made after two years. A decrease in Emotional functioning 
indicated a higher level of stress, depression, anxiety, and degree to which the PD 
interferes with participants’ usual life activities. Depression, stress, and anxiety may also 
be influenced by changes in lifestyle, relationships, drug treatment, and unrealistic 
expectations for the outcome (Leader & Leader, 2001) of the fetal tissue transplantation 
surgery.  
 Trajectory of change of the Social functioning dimension of QoL was also 
assessed. There was a significant cubic effect in participants’ level of perceived social 
support that was measured by the Social Provisions Scale (Cutrona & Russell, 1987). All 
three scores were within 1 standard deviation of the normative score of 82 (SD = 10; 
Cutrona & Russell, 1987). Participants’ scores indicated that Social functioning 
decreased between the baseline and two-year assessments. Level of perceived social 
support was greatly reduced between the two-year and current assessments from an 
average score of 83.33 to 72.89. This is quite an unusual result as perceived support does 
not typically change so dramatically over time (D. Russell, personal communication, June 
12, 2009). Figure 6 shows that of the nine participants reporting data on the current 
assessment, only three maintained or improved their scores in terms of perceived support. 
Given that the Physical and Emotional dimensions of QoL appeared to worsen over time, 
it is understandable that this could negatively impact participants’ level of perceived 
support from others, intimacy and relationships with others, and feeling recognized and 
respected by others (Cutrona & Russell, 1987).  
While perceived level of social support was significantly different in the current 
assessment, actual level of social support, as measured by the Social Contact Scale, was 
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not found to change significantly over time. Inspection of Figure 7, which shows the 
trajectory of change, indicates that participants appeared to have experienced a decline in 
actual support from others. Specifically, participants reported a decreased frequency in 
socializing with friends, telephone communication, and participation in public activities 
(McRae et al., 2004). These results are consistent with the decrease over time in 
participants’ level of perceived support. However, no causal relationships between the 
two types of social support can be established. It may be that a decline in Physical 
functioning impacted the frequency of being able to interact with others, which then led 
to a decrease in perceived social support. Even though there was a steady decline in the 
frequency of social interactions and activities with others, there was not found to be a 
statistically significant change over the four time periods that assessments were 
administered.  
 The second research question was to determine the trajectory of change for the 
five scales of the NEO-FFI for participants who participated in this study. According to 
existing research, the five factors of personality play an important role in producing 
individual differences in life satisfaction and other variables of well-being (Stephan, 
2009). The five-factors of the NEO-FFI have been shown to be relatively stable over 
time. These factors are considered to represent traits of personality that are persistent 
through adulthood (Costa, Metter, & McCrae, 1994; Sørlie & Sexton, 2004).  
Results of this analysis revealed significant differences among the participants for 
changes in Neuroticism, Extraversion, Openness to Experience, and Conscientiousness 
when comparing the baseline, one-year, two-year, and current assessments. 
Agreeableness did not change significantly over the four time periods. By looking at the 
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trajectory of change across the five factors, patients generally had a decrease in scores 
between the baseline and one-year assessments, and then an increase in scores between 
the one-year and two-year assessments. Finally, there was another decrease in scores 
between the two-year and current assessments. This pattern of change was found for the 
Extraversion, Openness to Experience, and Conscientiousness factors. In contrast, 
Neuroticism scores increased between the baseline and one-year assessments, and 
decreased between the one-year and two-year assessments. Neuroticism increased again 
between the two-year and current assessments.   
Results of the analysis of Neuroticism indicated there was a significant cubic 
change in Neuroticism over the baseline, one-year, two-year, and current assessments. 
Levels in Neuroticism increased until one year after surgery. Between one and two years 
after surgery, levels in Neuroticism decreased back down to a level similar to baseline.  
Scores across participants increased between the two-year and current assessments. The 
level of Neuroticism in the current study exceeded any other levels from prior 
assessments.  
Participants’ scores were at a mean of 14.88 at the baseline assessment, and then 
increased by two points at the one-year assessment. Levels of Neuroticism then decreased 
to 15 at the two-year assessment. Scores then increased to 19.25 with a regression to the 
mean (19.07) occurring between the two-year and current assessments (Costa & McCrae, 
1992). Figure 10 indicates that of the 10 participants who completed the current 
assessment, six of them had an increase in Neuroticism between the two-year and current 
assessments. Neuroticism was not found to be a stable variable of personality, as 
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evidenced by the significant cubic change over time. Mroczek and Spiro (2005) found 
that high levels of Neuroticism were related to low life satisfaction.   
There was also a significant cubic change in Extraversion across time. 
Participants appeared to feel less extraverted between the baseline and one-year 
assessments. Conversely, participants’ level of Extraversion increased between the one-
year and two-year assessments, though not as high as Extraversion was found to be at 
baseline. Finally, Extraversion decreased again between the two-year and current 
assessments, this time to the lowest level across the four time periods.  
Participants’ scores were at a mean of 30.88 at the baseline assessment, and then 
decreased by three points at the one-year assessment. Levels of Extraversion then 
increased to 29.88 at the two-year assessment. Scores then decreased to 26.88 with a 
regression to the mean (27.69) occurring between the two-year and current assessments 
(Costa & McCrae, 1992). Figure 12 indicates that of the 9 participants who completed the 
current assessment, five of them had a decrease in Extraversion between the two-year and 
current assessments. Extraversion was not assessed to be a stable variable of personality, 
as evidenced by the significant cubic change over time. Mroczek and Spiro (2005) also 
found that higher levels of Extraversion were related to greater life satisfaction.   
  A significant cubic change was also found for the factor Openness to 
Experience. Although levels of Openness to Experience decreased slightly between the 
baseline and one-year assessments (.5 points), and then increased between the one-year 
and two-year assessments (1.5 points), the factor appeared to remain relatively stable 
over the two year period. There was a more dramatic change in Openness to Experience 
between the two-year and current assessments (4 points).  
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Participants’ scores were at a mean of 34.63 at the baseline assessment, and then 
decreased by half a point at the one-year assessment. Levels of Openness to Experience 
then increased to 35.38 at the two-year assessment. Scores then decreased down to 31.38 
with a regression to the mean (27.03) occurring between the two-year and current 
assessments (Costa & McCrae, 1992). Figure 14 indicates that of the 10 participants who 
completed the current assessment, seven of them had a decrease in Openness to 
Experience between the two-year and current assessments. Openness to Experience was 
not found to be a stable variable of personality, as evidenced by the significant cubic 
change over time.  
There was a significant linear relationship for the Conscientiousness factor across 
time. Participants appeared to feel less Conscientiousness between the baseline and one-
year assessments. Participants felt slightly more Conscientiousness between the one-year 
and two-year assessments, and then significantly less between the two-year and current 
assessments.  
Participants’ scores were at a mean of 31.63 at the baseline assessment, and then 
decreased by two points at the one-year assessment. Levels of Conscientiousness then 
increased to 30.5 with a regression to the mean (34.57) occurring between the one-year 
and two-year assessments (Costa & McCrae, 1992). Scores then decreased to 27.75 
between the two-year and current assessments. Figure 18 indicates that of the 9 
participants who completed the current assessment, seven of them had a decrease in 
Conscientiousness between the two-year and current assessments. Similarly to the other 
factors of personality, Conscientiousness was not found to be a stable variable of 
personality, as evidenced by the significant linear change over time.   
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 In the present study, Neuroticism, Extraversion, Openness to Experience, and 
Conscientiousness were not found to be stable variables of personality over time. There 
have been varying theories as to whether brain tissue transplantation alters personality 
(Northoff, 1996). McRae et al. (2003) found that personality basically remained stable 
during a two-year follow-up for participants who had received fetal tissue transplantation. 
Mendelsohn, Dakof, and Skaff (1994) found a negative change in personality in 
Parkinson’s disease patients and suggested that it was due to the duration of the disease 
rather than aging. Previous research on the NEO with people who have medical 
conditions such as cancer and coronary disease has suggested that a change in health 
status did not affect personality (Costa, Metter, & McCrae, 1994). 
It is important to note that when looking at the individual scores of participants 
for the personality factors of the NEO-FFI, the majority of participants fell within one 
standard deviation of the normative scores for each factor. This indicates that the 
participants’ levels of personality were generally within “normal” limits. Overall, there 
does appear to be a regression to the mean effect for the personality variables. Although 
scores for some subscales (Extraversion, Open to Experience, and Agreeableness) 
initially were higher than normative scores, this may be explained in part by the nature of 
the experimental surgery and the types of individuals who were willing to participate in 
this type of procedure, where the collection of data attracted individuals who would be 
willing to take risks.  
Participants reported more neuroticism, feeling less extraverted, less open to 
experiences, and less conscientiousness since the initial surgical procedure that occurred 
10-12 years ago. This finding is consistent with participants’ decline in Physical 
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functioning, Emotional functioning, and perceived level of social support, as measured by 
the Social Provisions Scale (Cutrona & Russell, 1987). While some of these findings can 
perhaps be explained by progression of disease over time, other changes, as in the NEO-
FFI scales, are more difficult to explain. Unfortunately, the design precludes investigation 
of causal relationships in this study.   
 
Limitations of the Study 
 Several limitations exist in the present study. First, the sample size is small 
because the sample could only include the participants from the parent study (Freed et al., 
2001), who then participated in the original study on QoL (McRae et al., 2004). Thus, the 
potential sample size was only 30. Of that number, some participants in the original sham 
surgery group did not receive the transplant, some participants passed away, while others 
were either not able to be located due to outdated contact information or were not 
interested in participating in the current study. Because of the experimental nature of the 
study and the small sample size, the significance level was allowed to be .10, increasing 
the chance that a Type I error might have occurred.  
 Results from this study cannot be generalized to other individuals with PD; hence, 
this study has poor external validity. The results of the study may not be applicable to all 
Parkinson’s patients due to the inclusion and exclusion criteria used to recruit participants 
in the parent study (Freed et al., 2001). Also, this was a very unique study that involved 
experimental surgery to determine the effects of fetal tissue transplantation surgery on 
motor symptoms as well as QoL. Aside from the limitations of the study, it provided a 
unique opportunity to investigate the longitudinal changes over time regarding QoL with 
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a specific population of individuals who participated in an experimental surgical 
procedure. 
 Results demonstrated a general pattern of improvement over the one or two year 
period after surgery, followed by a decline to the current assessment. What the pattern of 
improvement or decline may have looked like between two years post-surgery and the 
current assessment is impossible to predict without the data. However, we do know that 
the pattern of change was not the same for everyone, as demonstrated by the figures 
showing individual data. Further investigation to determine differences between those 
who improved and those who declined is warranted.  
 
Recommendations for Future Research 
 Due to the small sample size, it is difficult to draw conclusions on fetal tissue 
transplantation surgery and QoL that are generalized to the greater population of those 
with PD. A recommendation for future studies is to assess the effects of treatment for PD 
with a larger sample size. The small sample size of this study resulted in limited external 
validity, low statistical power, and an increased risk of making a Type I error because of 
allowing the significance level to be .10. A larger sample would create an increase in 
statistical power, resulting in greater differentiation between the comparison of groups. 
However, because of the unique experimental nature of this study from the beginning, it 
is acknowledged that developing another study with a larger sample size will probably 
not happen.  
 Interestingly, participants’ level of perceived social support, as measured by the 
Social Provisions Scale, was found to significantly change over time, while participants’ 
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level of actual support, as measured by the Social Contact Scale, was not found to 
change. Although there was a decrease in visits with friends, telephone contact, and 
activities in public, the change was not statistically significant over time. On the other 
hand, participants’ level of perceived social support was significantly reduced by the 
current assessment. It is not known why participants reported such a decline in perceived 
social support while their frequency in interactions with others was not found to be 
statistically significant. It is interesting for there to be such a difference between 
perceived and actual level of support, and this would be a fascinating topic for further 
investigation.  
Further work is needed to identify exactly what contributed to changes in QoL 
and personality factors for participants in this study. It is important to determine, if 
possible, pre-surgical characteristics of those who improved versus those who declined 
over the period of the study. Further research is recommended to investigate QoL and 
changes in personality in older individuals in general, specifically when those individuals 
are managing a chronic illness. The results showing changes in four of the five scales of 
the NEO-FFI are clearly intriguing and suggest the need for further study.  
  
Conclusions 
The objective of the current study was to examine the changes in QoL for people 
who received fetal tissue transplantation for PD 10-12 years ago. This study is considered 
an important contribution to research on PD and QoL due to the unique nature of the 
sample and the longitudinal aspect of the study which incorporated assessments from four 
time periods.   
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The study found significant changes in several areas of QoL, including Physical 
functioning, Emotional functioning, and Social functioning, specifically the perceived 
level of social support. The study also found significant changes in the NEO-FFI 
personality factors of Neuroticism, Extraversion, Openness to Experience, and 
Conscientiousness over time. How these changes are related to one another and how and 
why some participants differed from others in terms of improvements and declines in 
functioning are questions for another study.   
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Appendix A 
Letter Sent to Participants with Questionnaire 
 
Dear   : 
 
It has been several years since you participated in the fetal tissue transplant study for the 
treatment of Parkinson’s disease. We thank you for all the time you gave to fill out our 
questionnaires related to quality of life at that time. Because we are interested in the long-
term effects of the surgery on patients and care partners/spouses, we would like to ask 
you to fill out an adapted version of previous questionnaires. I believe my assistant, 
Cindy Cole, has recently been in touch with you about your willingness to fill out this 
follow-up assessment.   
 
Enclosed are the follow-up questionnaires related to patient and caregiver perspectives’ 
of Parkinson’s disease since the neural transplant surgery. There are two versions of the 
questionnaires. The patient version is green and reads “Patient Version” at the top of the 
front page. The caregiver version is yellow and reads “Caregiver Version” at the top of 
the front page. Once you have completed the questionnaires, please return them to us in 
the postage-paid envelope we have provided. 
 
We really appreciate your participation in this project. Your responses are very important 
to us for better understanding your quality of life since the surgery. Once again, your 
identity will remain anonymous throughout the process of this study. We have enclosed 
one of the articles that explains some of the results of the earlier study. If you have any 
questions or concerns, please feel free to call me at (303) 871-2475 or email me at 
cmcrae@du.edu. Thank you again for your time and interest. 
 
Very sincerely, 
 
 
 
Cynthia McRae 
University of Denver 
Professor 
Chair, Counseling Psychology Program   
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Appendix B 
Unified Parkinson’s Disease Rating Scale (UPDRS) - Patient Version 
 
How well can you perform these daily activities AT YOUR BEST?  
(check one for each row) 
 
 Normal Adequate Limited Need Help Unable To Do 
 
Walking ____ ____ ____ ____ ____ 
Dressing ____ ____ ____ ____ ____ 
Cutting food ____ ____ ____ ____ ____ 
Hygiene ____ ____ ____ ____ ____ 
Getting up from chair   ____ ____ ____ ____ ____ 
Turning in bed              ____ ____ ____ ____ ____ 
Writing   ____ ____ ____ ____ ____ 
Talking     ____ ____ ____ ____ ____ 
 
 
 
 
How well can you perform these daily activities AT YOUR WORST?  
(check one for each row) 
 
 Normal Adequate Limited Need Help Unable To Do 
 
Walking ____ ____ ____ ____ ____ 
Dressing ____ ____ ____ ____ ____ 
Cutting food ____ ____ ____ ____ ____ 
Hygiene ____ ____ ____ ____ ____ 
Getting up from chair   ____ ____ ____ ____ ____ 
Turning in bed              ____ ____ ____ ____ ____ 
Writing   ____ ____ ____ ____ ____ 
Talking     ____ ____ ____ ____ ____ 
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Appendix C 
Severity of Symptoms 
 
Please rate the severity of each of the following problems AT YOUR BEST. 
(check one for each row) 
 
 Normal Mild Moderate Severe Very Severe 
 
Tremor ____ ____ ____ ____ ____ 
Swallowing ____ ____ ____ ____ ____ 
Salivation ____ ____ ____ ____ ____ 
Freezing when walking     ____ ____ ____ ____ ____ 
Falling ____ ____ ____ ____ ____ 
       
  
       
  
 
Please rate the severity of each of the following problems AT YOUR WORST. 
(check one for each row) 
 
 Normal Mild Moderate Severe Very Severe 
 
Tremor ____ ____ ____ ____ ____ 
Swallowing ____ ____ ____ ____ ____ 
Salivation ____ ____ ____ ____ ____ 
Freezing when walking     ____ ____ ____ ____ ____ 
Falling ____ ____ ____ ____ ____ 
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Appendix D 
Free or Restricted Scale 
 
Overall, how free or restricted do you feel in doing what you want to do? 
(check or circle the appropriate number) 
 
 
1         2         3         4         5         6        7   
I still do everything      I can no longer do the 
   I want to do            things I want to do
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Appendix E 
Parkinson’s Disease Stress Scale 
Below you will find a list of stressful situations that may occur because of your physical 
symptoms.  Please check “Yes” or “No” to indicate whether or not an item causes you 
considerable stress, or clearly bothers you.  
 
Yes  No 
 
____ ____ 1. Sometimes I am embarrassed in public because of my symptoms. 
 
____ ____ 2. I attract attention in public because of my symptoms. 
 
____ ____ 3. Friends and acquaintances do not take my symptoms seriously. 
 
____ ____ 4. I cannot make new friends because of my disease. 
 
____ ____ 5. I am anxious about the uncertainty of the future of my disease. 
 
____ ____ 6. I worry a great deal about my symptoms. 
 
____ ____ 7. I worry so much about my disease that all other things become 
unimportant. 
 
____ ____ 8. My physical condition tends to determine all that I think and do. 
 
____ ____ 9. I feel like a disabled person. 
 
____ ____ 10. I feel a sense of helplessness and anger because I cannot influence 
my disease. 
 
____ ____ 11. The lives of my loved ones have changed because of my disease. 
 
____ ____ 12. Even members of my family cannot really understand the  
difficulties I face.  
 
____ ____ 13.  My partner and my family take too little notice of my disease. 
 
____ ____ 14. I am concerned that my family members restrict themselves too 
much because of my disease. 
 
____ ____ 15. Sometimes I think my partner may leave me because of my disease. 
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Appendix E, continued 
Parkinson’s Disease Stress Scale 
Below you will find a list of stressful situations that may occur because of your physical 
symptoms.  Please check “Yes” or “No” to indicate whether or not an item causes you 
considerable stress, or clearly bothers you.  
 
Yes  No 
 
____ ____ 16.  Because of my disease I have had to give many personal  
responsibilities over to my partner or family members. 
 
____ ____ 17.  Because of my disease I have had to give up my job. 
 
____ ____ 18. I have the impression that my disease is not being treated properly 
by my doctor. 
 
____ ____ 19.  I often cannot ask all my questions when I am with the doctor. 
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Appendix F 
The Center for Epidemiologic Studies Scale (CESD) 
Below is a list of ways you might have felt during the past week. Please indicate how 
often you felt or acted the way each statement suggests by using the following scale: 
 
Rarely or none of the time (Less than 1 day) 
Some or a little of the time (1-2 days) 
Occasionally or a moderate amount of time (3-4 days) 
Most all of the time (5-7 days) 
 
 Rarely Some of 
the Time 
Moderate 
Amount 
of Time 
 
Most of 
the Time 
1. I was bothered by things that usually 
don’t bother me. 
 
_____ _____ _____ _____ 
2. I did not feel like eating; my appetite 
was poor. 
 
_____ _____ _____ _____ 
3. I felt that I could not shake off the 
blues even with help from my family or 
friends. 
 
_____ _____ _____ _____ 
4. I felt that I was just as good as other 
people. 
 
_____ _____ _____ _____ 
5. I had trouble keeping my mind on what 
I was doing.     
 
_____ _____ _____ _____ 
6. I felt depressed. 
 
_____ _____ _____ _____ 
7. I felt that everything I did was an 
effort. 
 
_____ _____ _____ _____ 
8. I felt hopeful about the future. 
 
_____ _____ _____ _____ 
9. I thought my life had been a failure. 
 
_____ _____ _____ _____ 
10. I felt fearful. 
 
_____ _____ _____ _____ 
11. My sleep was restless. 
 
_____ _____ _____ _____ 
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Appendix F, continued 
The Center for Epidemiologic Studies Scale (CESD) 
Below is a list of ways you might have felt during the past week. Please indicate how 
often you felt or acted the way each statement suggests by using the following scale: 
 
Rarely or none of the time (Less than 1 day) 
Some or a little of the time (1-2 days) 
Occasionally or a moderate amount of time (3-4 days) 
Most all of the time (5-7 days) 
 
 
 
Rarely Some of 
the Time 
Moderate 
Amount 
of Time 
 
Most of 
the Time 
12. I was happy. _____ _____ _____ _____ 
13. I talked less than usual. _____ _____ _____ _____ 
14. I felt lonely. _____ _____ _____ _____ 
15. People were unfriendly. _____ _____ _____ _____ 
16. I enjoyed life. _____ _____ _____ _____ 
17. I had crying spells. _____ _____ _____ _____ 
18. I felt sad. _____ _____ _____ _____ 
19. I felt that people disliked me. _____ _____ _____ _____ 
20. I could not get “going.” _____ _____ _____ _____ 
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Appendix G 
State-Trait Anxiety Inventory-State 
Listed below are a number of statements that people have used to describe themselves. 
Read each statement and then indicate how you feel at the present moment (check one 
answer for each item). 
 
 Not At All Somewhat Moderately Very Much 
 
1.  I feel calm. _____ _____ _____ _____ 
 
2.  I feel secure. _____ _____ _____ _____ 
 
3.  I am tense. _____ _____ _____ _____ 
 
4.  I am regretful. _____ _____ _____ _____ 
 
5.  I am at ease. _____ _____ _____ _____ 
 
6.  I feel upset. _____ _____ _____ _____ 
 
7. I am worrying over 
possible misfortunes. 
 
_____ _____ _____ _____ 
8.  I feel rested. _____ _____ _____ _____ 
 
9.  I feel anxious. _____ _____ _____ _____ 
 
10. I feel comfortable. _____ _____ _____ _____ 
 
11. I feel self-confident. _____ _____ _____ _____ 
 
12. I feel nervous. _____ _____ _____ _____ 
 
13. I am jittery. _____ _____ _____ _____ 
 
14. I feel “high-strung.” _____ _____ _____ _____ 
 
15. I am relaxed. _____ _____ _____ _____ 
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Appendix G, continued 
State-Trait Anxiety Inventory-State 
Listed below are a number of statements that people have used to describe themselves. 
Read each statement and then indicate how you feel at the present moment (check one 
answer for each item). 
  
 Not At All Somewhat Moderately Very Much 
 
16. I feel content. _____ _____ _____ _____ 
 
17. I am worried. _____ _____ _____ _____ 
 
18. I feel over-excited and 
“rattled.” 
 
_____ _____ _____ _____ 
19. I feel joyful. _____ _____ _____ _____ 
 
20. I feel pleasant. _____ _____ _____ _____ 
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Appendix H 
Intrusiveness of Illness Scale 
Using the scale below, check or circle the number that expresses how much you feel your 
Parkinson’s disease interferes with the following aspects of your life. 
 
My illness interferes with my… 
 
       Very Little               A Great Deal 
 
Body Image    1         2         3         4        5        6         7   
 
Eating Habits    1         2         3         4        5        6         7   
 
Ability to Work   1         2         3         4        5        6         7   
 
Financial Security   1         2         3         4        5        6         7   
 
Preferred Recreation/Leisure  1         2         3         4        5        6         7   
 
Responsibility in the Family  1         2         3         4        5        6         7   
 
Family Relationships   1         2         3         4        5        6         7   
 
Marital Relationships   1         2         3         4        5        6         7   
 
Sexual Relationships   1         2         3         4        5        6         7   
 
Personal Relationships with Friends 1         2         3         4        5        6         7   
 
Plans for the Future   1         2         3         4        5        6         7   
 
Freedom to Choose Time Alone 1         2         3         4        5        6         7   
 
Ability to Express My Personality 1         2         3         4        5        6         7   
 
Sense of Independence  1         2         3         4        5        6         7   
 
Self-Esteem    1         2         3         4        5        6         7   
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Appendix I 
NEO Five-Factor Inventory (NEO-FFI) 
Circle the response that best represents your opinion.  
Circle SD if you strongly disagree or the statement is definitely false.  
Circle D if you disagree or the statement is mostly false.  
Circle N if you are neutral on the statement, if you cannot decide, or if the statement is 
about equally true and false. 
Circle A if you agree or the statement is mostly true. 
Circle SA if you strongly agree or the statement is definitely true.  
 
1. I am not a worrier. SD D N A SA 
2. I like to have a lot of people around me.  SD D N A SA 
3. I don’t like to waste my time  SD D N A SA 
daydreaming.  
4. I try to be courteous to everyone SD D N A SA 
I meet. 
 
5. I keep my belongings neat and clean. SD D N A SA 
6. I often feel inferior to others. SD D N A SA 
7. I laugh easily. SD D N A SA 
8. Once I find the right way to do  SD D N A SA 
something, I stick to it. 
 
9. I often get into arguments with my  SD D N A SA 
family and co-workers. 
 
10. I’m pretty good about pacing  SD D N A SA 
myself so as to get things done on time.  
 
11. When I’m under a great deal of stress,  SD D N A SA 
sometimes I feel like I’m going to pieces. 
 
12. I don’t consider myself especially SD D N A SA  
“light-hearted.” 
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Appendix I, continued 
NEO Five-Factor Inventory (NEO-FFI) 
SD = Strongly Disagree  
D = Disagree   
N = Neutral 
A = Agree  
SA = Strongly Agree  
 
13. I am intrigued by the patterns I  SD D N A SA 
find in art and nature. 
 
14. Some people think I’m selfish SD D N A SA 
and egotistical. 
 
15. I am not a very methodical person. SD D N A SA 
16. I rarely feel lonely or blue. SD D N A SA 
17. I really enjoy talking to people. SD D N A SA 
18. I believe letting students hear SD D N A SA 
controversial speakers can only confuse  
and mislead them. 
 
19. I would rather cooperate with others SD D N A SA 
than compete with them. 
 
20. I try to perform all the tasks assigned SD D N A SA 
to me conscientiously.  
 
21. I often feel tense and jittery. SD D N A SA 
22. I like to be where the action is. SD D N A SA 
23. Poetry has little or no effect on me. SD D N A SA 
24. I tend to be cynical and skeptical SD D N A SA 
of others’ intentions. 
 
25. I have a clear set of goals and work SD D N A SA 
toward them in an orderly fashion. 
 
26. Sometimes I feel completely worthless. SD D N A SA 
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Appendix I, continued 
NEO Five-Factor Inventory (NEO-FFI) 
SD = Strongly Disagree  
D = Disagree   
N = Neutral 
A = Agree  
SA = Strongly Agree  
 
27. I usually prefer to do things alone. SD D N A SA 
28. I often try new and foreign foods. SD D N A SA 
29. I believe that most people will take SD D N A SA 
advantage of you if you let them. 
 
30. I waste a lot of time before settling SD D N A SA 
down to work. 
 
31. I rarely feel fearful or anxious. SD D N A SA 
32. I often feel as if I’m bursting with  SD D N A SA 
energy. 
 
33. I seldom notice the moods or  SD D N A SA 
feelings that different environments produce. 
 
34. Most people I know like me. SD D N A SA 
35. I work hard to accomplish my goals. SD D N A SA 
36. I often get angry at the way people SD D N A SA  
treat me. 
 
37. I am a cheerful, high-spirited person. SD D N A SA 
38. I believe we should look to our SD D N A SA 
religious authorities for decisions on moral  
issues. 
 
39. Some people think of me as cold and  SD D N A SA 
calculating 
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Appendix I, continued 
NEO Five-Factor Inventory (NEO-FFI) 
SD = Strongly Disagree  
D = Disagree   
N = Neutral 
A = Agree  
SA = Strongly Agree  
 
40. When I make a commitment, I can  SD D N A SA 
always be counted on to follow through. 
 
41. Too often, when things go wrong, I  SD D N A SA 
get discouraged and feel like giving up. 
 
42. I am not a cheerful optimist. SD D N A SA 
 
43. Sometime when I am reading poetry  SD D N A SA 
or looking at a work of art, I feel a chill or  
wave of excitement.  
 
44. I’m hard-headed and tough-minded SD D N A SA 
in my attitudes. 
 
45. Sometimes I’m not as dependable SD D N A SA 
or reliable as I should be. 
 
46. I am seldom sad or depressed. SD D N A SA 
47. My life is fast-paced. SD D N A SA 
48. I have little interest in speculating SD D N A SA 
on the nature of the universe or the  
human condition. 
49. I generally try to be thoughtful and  SD D N A SA 
considerate.  
 
50. I am a productive person who  SD D N A SA 
always gets the job done. 
 
51. I often feel helpless and want  SD D N A SA 
someone else to solve my problems. 
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Appendix I, continued 
NEO Five-Factor Inventory (NEO-FFI) 
SD = Strongly Disagree  
D = Disagree   
N = Neutral 
A = Agree  
SA = Strongly Agree  
 
52. I am a very active person. SD D N A SA  
53. I have a lot of intellectual curiosity. SD D N A SA 
54. If I don’t like people, I let them  SD D N A SA 
know it. 
 
55. I never seem to be able to get  SD D N A SA 
organized.  
 
56. At times I have been so ashamed SD D N A SA 
I just wanted to hide. 
 
57. I would rather go my own way SD D N A SA 
than be a leader of others.  
 
58. I often enjoy playing with theories SD D N A SA 
or abstract ideas. 
 
59. If necessary, I am willing to  SD D N A SA 
manipulate people to get what I want. 
 
60. I strive for excellence in everything  SD D N A SA 
I do.   
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Appendix J 
Social Provisions Scale (SPS) 
In answering the following questions, think about your current relationships with friends, 
family members, co-workers, community members, and so on.  Please indicate to what 
extent each statement describes your current relationships with other people (check one 
answer for each item). 
 
 Strongly 
Disagree 
 
Disagree Agree Strongly 
Agree 
1. There are people I can depend on to 
help me if I really need it.   
              
_____ _____ _____ _____ 
2. I feel that I do not have close personal 
relationships with other people.  
 
_____ _____ _____ _____ 
3. There is no one I can turn to for 
guidance in times of stress. 
              
_____ _____ _____ _____ 
4. There are people who depend on me for 
help. 
 
_____ _____ _____ _____ 
5. There are people who enjoy the same 
social activities I do.  
 
_____ _____ _____ _____ 
6. Other people do not view me as 
competent.  
 
_____ _____ _____ _____ 
7. I feel personally responsible for the 
well-being of another person. 
 
_____ _____ _____ _____ 
8. I feel part of a group who share my 
attitudes and beliefs. 
 
_____ _____ _____ _____ 
9. I do not thing other people respect my 
skills and abilities. 
 
_____ _____ _____ _____ 
10. If something went wrong, no one 
would come to my rescue. 
 
_____ _____ _____ _____ 
11. I have close relationships that provide 
me with a sense of emotional security and 
well-being. 
_____ _____ _____ _____ 
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Appendix J, continued 
Social Provisions Scale (SPS) 
 Strongly 
Disagree 
 
Disagree Agree Strongly 
Agree 
12. There is someone I could talk to about 
important decisions in my life.  
 
_____ _____ _____ _____ 
13. I have relationships where my 
competence and skill are recognized. 
 
_____ _____ _____ _____ 
14. There is no one who shares my 
interests and concerns.  
 
_____ _____ _____ _____ 
15. There is no one who really relies on 
me for their well-being.  
 
_____ _____ _____ _____ 
16. There is a trustworthy person I could 
turn to for advice if I were having 
problems. 
 
_____ _____ _____ _____ 
17. I feel a strong emotional bond with at 
least one other person. 
 
_____ _____ _____ _____ 
18. There is no one I can depend on for 
aid if I really need it. 
 
_____ _____ _____ _____ 
19. There is no one I feel comfortable 
talking about problems with. 
 
_____ _____ _____ _____ 
20. There are people who admire my 
talents and abilities.  
 
_____ _____ _____ _____ 
21. I lack a feeling of intimacy with 
another person. 
 
_____ _____ _____ _____ 
22.  There is no one who likes to do the 
things I do. 
 
_____ _____ _____ _____ 
23.  There are people I can count on in an 
emergency. 
 
_____ _____ _____ _____ 
24.  No one needs me to care for them. _____ _____ _____ _____ 
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Appendix K 
Social Contact Scale 
 
During the past month, about how often did you get together socially with friends or 
relatives? (check one) 
 
____Not at all      ____About once a week 
____Once in the past month    ____Several days a week 
____2 or 3 times in the past month   ____Every day 
 
How happy are you with this level of contact? 
    1         2         3         4         5         6        7   
            Not at all happy          Extremely happy 
 
 
 
About how often were you on the telephone with close friends or relatives during the past 
month? (check one) 
 
____Not at all      ____About once a week 
____Once in the past month    ____Several days a week 
____2 or 3 times in the past month   ____Every day 
 
How happy are you with this level of contact? 
    1         2         3         4         5         6        7   
            Not at all happy          Extremely happy 
 
 
 
During the past month, about how often have you done things in public such as shopping, 
eating in restaurants, going to concerts or movies, etc.? (check one) 
 
____Not at all      ____About once a week 
____Once in the past month    ____Several days a week 
____2 or 3 times in the past month   ____Every day 
 
How happy are you with this level of contact? 
    1         2         3         4         5         6        7   
            Not at all happy         Extremely happy 
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Appendix L 
 
Participant Demographics 
 
Information About You 
 
1. What is your current living situation? (check one) 
 
_____Living with a partner or family member 
_____Living with a friend or roommate 
_____Living alone 
_____Living in a residential setting 
 
2. What is your current marital status? (check one) 
 
_____Never been married 
_____Married or living with partner 
_____Separated or divorced 
_____Widowed 
 
3. If you are married to your partner, how long have you been married? _____ 
 
4. If you are married, is this your: (check one) 
 
_____first marriage 
_____second marriage 
_____third marriage 
 
5. Do you have paid employment right now? (check one) 
 
_____No 
_____Yes, part-time 
_____Yes, full-time 
 
6. Do you currently do any volunteer work? 
 
_____Yes  
_____No 
_____I used to, but no longer do 
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Appendix L, continued 
 
Participant Demographics 
 
7. If not currently employed, what is the main reason? (please check one box only) 
 
_____Temporarily laid off 
_____Retired by my own choice 
_____Forced to retire by my employer 
_____Retired on physician’s advice 
_____Homemaker 
_____Poor health 
_____My job was too stressful, or physically demanding 
_____Other reason (specify): ________________________________________ 
 
8. Do you have any other chronic health problems (e.g., diabetes, heart condition, high 
blood pressure)? (check one) 
 
_____Yes If yes, please describe: _________________________________________ 
_____No 
